Document:

Exhibit 10.11

 

CONFIDENTIAL PORTIONS OF THIS AGREEMENT
HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR SUCH PORTIONS. ASTERISKS
DENOTE OMISSIONS.

 

AMENDED AND RESTATED LICENSE AGREEMENT

 

This Amended and Restated License Agreement
("Agreement") is entered into as of July 31, 2017 ("Restated Agreement Effective Date"), by and
between Albert Einstein College of Medicine, Inc., a corporation organized and existing under the laws of the State of New York,
having an office and place of business at 1300 Morris Park Avenue, Bronx, New York 10461 as successor-in-interest to Albert Einstein
College of Medicine of Yeshiva University, a Division of Yeshiva University, ("Licensor") and Cue Biopharma Inc.,
formerly known as Imagen Biopharma, Inc., a corporation organized and existing under the laws of the State of Delaware, having
an office and place of business at do MDB Capital Group LLC, 401 Wilshire Blvd, Suite 1020, Santa Monica, California 90401 ("Licensee").

 

Statement

 

Licensor is the owner of certain patent
rights naming Steven C. Almo, Ronald D. Seidel, Brandan S. Hillerich, Rodolfo J. Chaparro, Sarah C. Garrett-Thomson, Scott J. Garfoth
and James D. Love ("the Investigators") as inventors, which relate to methods for high throughput receptor-ligand
identification, a cellular platform for rapid and comprehensive T-cell immunomonitoring and SYNTAC Fc fusion constructs and uses
thereof.

 

Licensor is also the owner of certain know-how
relating to synapse for targeted T-cell activation (synTac) molecules, receptor ligand identification, and platforms for T-cell
immunomonitoring. Licensee wishes to acquire an exclusive license in the Field (as defined below) from Licensor with respect to
the aforementioned patent rights and know-how.

 

Licensee and Licensor are parties to a License
Agreement effective January 14, 2015, as amended pursuant to Amendment No. 1 to the License Agreement, effective June 2, 2015 and
pursuant to a Second Amendment Agreement effective April 19, 2016 (collectively, the "Original License"). Licensee
and Licensor now desire to amend and restate the Original License to modify certain terms, including adding a license to sell Know-How
Products and MHC Class Il Products, as hereinafter defined

 

NOW, THEREFORE, in consideration
of the promises and mutual covenants, conditions and limitations herein contained and other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, Licensor and Licensee agree as follows:

 

    	 	- 1 -	 

     

    

 

		1.	Definitions

 

		1.01	“Field” means any and all uses under the Agreement Patents and Know-How.

 

		1.02	“Agreement Patents” means the patent applications listed on Appendix A, together with any and all patents
and patent applications which issue from or are based on such patent applications and from any and all divisionals, continuations,
continuations-in-part (but only to the extent the claims thereof are enabled by disclosure of the parent application) and foreign
counterparts of such patent applications, and any and all reissues, renewals and extensions or the like of such patent applications
and any and all U.S. and foreign patents which are based on such patent applications. Appendix A shall be updated from time-to-time
by the parties.

 

		1.03	“Original Effective Date” shall mean January 14, 2015.

 

		1.04	Licensed Product” means any product, process or service in the Field, the development, manufacture, use, provision,
sale or import of which is covered by a Valid Claim in an Agreement Patent in the country of manufacture and/or sale.

 

		1.05	“Know-How” means technology received by Licensee from Licensor relating to synapse for targeted T-cell activation
(synTac) molecules, receptor ligand identification, or platforms for T-cell immunomonitoring.

 

		1.06	“Know-How Product” means any product or service (or component thereof), other than a Licensed Product or
an MHC Class II Product, the discovery, development, manufacture, use, sale, offering for sale, importation, exportation, distribution,
rental or lease of which involves the use of or incorporation, in whole or in part, of Know-How. For clarity, a product or service
(or component thereof) that includes polypeptides of the major histocompatibility complex Class II grouping but is not a MHC Class
II Product, will be considered a Know-How Product if the discovery, development, manufacture, use, sale, offering for sale, importation,
exportation, distribution, rental or lease of which involves the use of or incorporation, in whole or in part, of Know-How.

 

		1.07	“MHC Class II Products” means any Licensed Product that includes polypeptides of the major histocompatibility
complex Class II grouping.

 

		1.08	“Net Sales” means the total consideration, in any form, received as consideration for the sale, lease, provision
or other disposition of Licensed Products, Know-How Products and/or MHC Class II Products by Licensee and/or Affiliates to an independent
third party ("Total Consideration"), less:

 

    	 	- 2 -	 

     

    

  

		(a)	customary trade and quantity discounts actually allowed, refunds, returns and recalls; and,

 

		(b)	when included in gross sales, customary freight, insurance, storage, shipping, duties, and sales, V.A.T. and/or use taxes based
on sales prices, but not including taxes when assessed on incomes derived from such sales.

 

With respect to consideration received by Licensee
and Affiliates, the total deductions referenced in Sub-sections (a) and (b) of this Section 1.04 shall not exceed [***] of the
Total Consideration for Licensed Products, Know-How Products and MHC Class II Products in any calendar quarter.

 

If Licensee and/or Affiliates intend to accept from
independent third parties any non-cash consideration as Net Sales or intend to provide Licensed Product, Know-How Products and/or
MHC Class lI Products at no charge, Licensee must first notify Licensor in writing in reasonable detail. If the parties can not
agree on the present day value of such non-cash consideration, then the parties will appoint an independent third party to determine
the present day value of such consideration and that value shall be added to Net Sales in place of the non-cash consideration.
The cost of the independent third party will be paid by Licensee.

 

In the event that, during a particular calendar quarter,
a Licensed Product, Know-How Product or MHC Class II Product is sold in combination with one or more other products, whether or
not such other products are packaged or otherwise physically combined with such Licensed Product, Know-How Product or MHC Class
II Product for a single price (a "Combination Product"), Net Sales from sales of a Combination Product, for purposes
of calculating royalties due under this Agreement, shall be calculated by multiplying the Net Sales of the Combination Product
by the fraction AI(A+B), where A is the average per unit sales price for such calendar quarter of the Licensed Product, Know-How
Product or MHC Class it Product sold separately in the country of sale and B is the average per unit sales price for such calendar
quarter of the other product(s) sold separately in the country of sale. In the event that no separate sales are made of the Licensed
Product, Know-How Product or MHC Class II Product on the one hand, and/or the other product(s) in the country of sale on the other
hand, separate sale prices in commensurate countries may be used instead. In the event that no separate sales are made of the Licensed
Product, Know-How Product or MHC Class II Product on the one hand, and/or the other product(s) on the other, Net Sales from sales
of a Combination Product, for purposes of determining royalty payments on such Combination Products, shall be calculated using
the entire Net Sales of such Combination Products.

 

    	 	- 3 -	 

     

    

 

		1.09	“Net Proceeds” shall mean, subject to the exception discussed in sub-section (a) below, the total consideration
in any form received by Licensee from a Sublicensee or optionee in connection with the grant to said Sublicensee or optionee of
rights under Agreements Patents and/or Know-How. Net Proceeds includes, without limitation, license signing fees, maintenance fees,
milestone and minimum payments (whether or not such fees and payments are creditable against future royalties to be paid to Licensee),
and just that portion of the funds received for equity purchases of Licensee which exceeds the fair market value of the equity
based on the most recent sales price of Licensee’s equity securities (or if Licensee is a public company at such time, the
average closing price of the immediately preceding 5 trading days) exclusive of transactions covered by Licensee’s equity
incentive plans.

 

		(a)	Net Proceeds does not include royalties based on Sublicensee Net Sales, and Contract Research.

 

If Licensee intends to accept from a Sublicensee or
optionee any non-cash consideration as Net Proceeds, Licensee must first notify Licensor in writing in reasonable detail. Licensor
shall be deemed to have accepted the transaction unless Licensor notifies Licensee in writing of Licensor’s objection in
reasonable detail within 5 business days of receipt of Licensee’s written notice. if the parties can not agree on the present
day value of such non-cash consideration, then the parties will appoint an independent third party to determine the present day
value of such consideration and that value shall be added to Net Proceeds in place of the non-cash consideration. The cost of the
independent third party will be paid by Licensee.

 

		1.10	“Contract Research” shall mean those funds received by Licensee from a Sublicensee in connection with the
grant to said Sublicensee of rights under Agreement Patents and/or Know-How, which funds are actually used to pay for research
and/or development by Licensee relating directly to Licensed Products, Know-How Products and/or MHC Class II Products, which work
is to be performed by or for Licensee after the date of the sublicense agreement and with results to be reported to Licensor and
licensed to Sublicensee and which is to be performed at a total cost that does not exceed Licensee’s direct costs. Notwithstanding
the foregoing, Contract Research funds received from a Sublicensee which are in excess of [***] of the total consideration received
by Licensee from that Sublicensee in connection with the grant to said Sublicensee of rights under Agreement Patents and/or Know-How
in any twelve month period beginning [***] after the Restated Agreement Effective Date shall be excluded from the definition of
Contract Research and included in the definition of Net Proceeds, unless otherwise approved at the time of execution of the relevant
sublicense by Licensor.

 

    	 	- 4 -	 

     

    

 

		1.11	“Sublicensee Net Sales” means the total consideration, in any form, received as consideration for the sale,
lease, provision or other disposition of Licensed Products, Know-How Products and/or MHC Class II Products by a Sublicensee to
an independent third party ("Sublicensee Total Consideration"), less:

 

		(a)	customary trade and quantity discounts actually allowed, refunds, returns and recalls; and,

 

		(b)	when included in gross sales, customary freight, insurance, storage, shipping, duties, and sales, V.A.T. and/or use taxes based
on sales prices, but not including taxes when assessed on incomes derived from such sales.

 

With respect to consideration received by Sublicensee,
the total deductions referenced in Sub-sections (a) and (b) of this Section 1.11 shall not exceed [***] of the Sublicensee Total
Consideration for Licensed Products, Know-How Products and MHC Class II Products in any calendar quarter.

 

If a Sublicensee intends to accept from independent
third parties any non-cash consideration as Sublicensee Net Sales or intends to provide Licensed Product, Know-How Products and/or
MHC Class II Products at no charge, Licensee must first notify Licensor in writing in reasonable detail. If Licensee and Licensor
can not agree on the present day value of such non-cash consideration, then Licensee and Licensor will appoint an independent third
party to determine the present day value of such consideration and that value shall be added to Sublicensee Net Sales in place
of the non-cash consideration. The cost of the independent third party will be paid by Licensee.

 

    	 	- 5 -	 

     

    

 

In the event that, during a particular calendar quarter,
a Licensed Product, Know-How Product or MHC Class II Product is sold in combination with one or more other products, whether or
not such other products are packaged or otherwise physically combined with such Licensed Product, Know-How Product or MHC Class
II Product for a single price (a "Sublicensee Combination Product"), Sublicensee Net Sales from sales of a Sublicensee
Combination Product, for purposes of calculating royalties due under this Agreement, shall be calculated by multiplying the Sublicensee
Net Sales of the Sublicensee Combination Product by the fraction A/(A+B), where A is the average per unit sales price for such
calendar quarter of the Licensed Product, Know-How Product or MHC Class II Product sold separately in the country of sale and B
is the average per unit sales price for such calendar quarter of the other product(s) sold separately in the country of sale. In
the event that no separate sales are made of the Licensed Product, Know-How Product or MHC Class II Product on the one hand, and/or
the other product(s) in the country of sale on the other hand, separate sale prices in commensurate countries may be used instead.
In the event that no separate sales are made of the Licensed Product, Know-How Product or MHC Class II Product on the one hand,
and/or the other product(s) on the other, Sublicensee Net Sales from sales of a Sublicensee Combination Product, for purposes of
determining royalty payments on such Sublicensee Combination Products, shall be calculated using the entire Sublicensee Net Sales
of such Sublicensee Combination Products.

 

		1.12	“Affiliate” means any entity that, directly or indirectly, through one or more intermediates, controls,
is controlled by, or is under common control with Licensee. For the purposes of this definition, control shall mean the direct
or indirect ownership of at least Fifty Percent (50%) of (i) the stock shares entitled to vote for the election of directors
or (ii) ownership interest.

 

		1.13	“Sublicensee” shall mean any non Affiliate third party to whom Licensee has granted the right to make and
sell (or otherwise dispose of) Licensed Products and/or Know-How Products and/or MHC Class II Products.

 

		1.14	“Confidential Information” means any information designated as such in writing by the disclosing party,
whether by letter or by the use of an appropriate proprietary stamp or legend, prior to or at the time any such confidential or
proprietary materials or information are disclosed by the disclosing party to the recipient. Notwithstanding the foregoing, information
or materials which are orally or visually disclosed to the recipient by the disclosing party, or are disclosed in a writing or
other tangible form without an appropriate letter, proprietary stamp or legend, shall constitute Confidential Information if the
disclosing party, within ten (10) days after such disclosure, delivers to the recipient a written or electronic document or documents
describing such information or materials and referencing the place and date of such oral, visual, written or other tangible disclosure.

 

    	 	- 6 -	 

     

    

 

		1.15	“Valid Claim” means (i) a claim of a pending patent application included within the Agreement Patents that
continues to be prosecuted in good faith for a period of not more than [***] from the date of filing of the national application
including such claim and/or (ii) a claim of an issued and unexpired patent included within the Agreement Patents which has not
been revoked or held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction,
unappealable or unappealed within the time allowed for appeal, or which has not been disclaimed, denied or admitted to be invalid
or unenforceable through reissue or disclaimer or otherwise.

 

		1.16	“Fully-Diluted, as Converted Basis” shall mean the total number of shares of Licensee's capital stock calculated
to include (1) all issued and outstanding shares of Common Stock, excluding treasury shares, (2) all shares of Common Stock issuable
upon the conversion or exchange of Licensee's debt or equity securities directly or indirectly convertible into or exchangeable
for Common Stock (“Convertible Securities”), (3) all shares of Common Stock issuable upon the exercise of all
then outstanding rights, options or warrants to subscribe for, purchase or otherwise acquire Common Stock or Convertible Securities,
whether or not then exercisable or convertible, and (4) to the extent the number of securities reserved for future issuance (the
“Share Reserve”) pursuant to any Licensee equity incentive plan, stock option or similar plan in effect at the
time of calculation exceeds [***] of the issued and outstanding shares of Common Stock, the amount of such excess shall be assumed
issued and granted and included in such calculation.

 

		1.17	“Funding Threshold” shall mean that Licensee has received total net proceeds of an aggregate of [***] in
cash in consideration for the sale of shares of Licensee’s capital stock or Convertible Securities pursuant to bona fide
financing(s) in a transaction or series of related transactions.

 

		1.18	“Liquidity Event” shall mean the first to occur of either (i) a public offering registered under Section
5 of the Securities Act of 1933, as amended (the “Securities Act”), or any other transaction or series of transactions
in which Licensee or an entity into which Licensee merges, or an Affiliate thereof, becomes or is a public reporting company, or
the wholly-owned subsidiary of a public reporting company, pursuant to Section 12 of the Securities Exchange Act of 1934, as amended
(the “Exchange Act), or becomes a listed company on a non-U.S. exchange, or the wholly-owned subsidiary of a listed
company on a non-U.S. exchange (a “Going Public Event”), or (ii) any of the following in a single transaction
or series of related transactions: (a) a merger, consolidation, reorganization, transfer of Licensee securities, or similar transaction,
in which the stockholders of Licensee immediately prior to such transaction possess less than a majority of the voting power of
Licensee or any successor entity’s issued and outstanding capital stock immediately after such transaction; or (b) a disposition
to one or more persons who are not Affiliates of Licensee of all or substantially all of (y) Licensee’s assets determined
on a consolidated basis or (z) Licensee’s business to which the License Agreement relates.

 

    	 	- 7 -	 

     

    

 

		1.19	“Competing Product” shall mean a product that (i) is sold in a country where there is a Valid Claim, but
is not covered by a Valid Claim, (ii) is a molecule that couples an antigen for targeted T-cell activation or attenuation, and
at least one co-stimulatory ligand for activating or attenuating a T-cell response, (iii) binds to the same molecular target(s)
as a Licensed Product, and (iv) has been approved by the applicable regulatory authority and is being sold in such country by a
third party for use at least one of the same indications as a Licensed Product.

 

		1.20	“Sublicensee Product” shall mean a Licensed Product, Know-How Product and/or MHC Class II Product sold by
a Sublicensee.

 

		2.	Licensor’s Agreements With U.S. Government

 

		2.01	Licensor, through its Investigators, has and will perform research sponsored in part by the United States Government and related
to the Field. As a result of this government sponsorship of the aforementioned research, the United States Government retains certain
rights in such research as set forth in 35 U.S.C. §200 et. seq. and applicable regulations.

 

		2.02	The continuance of such government sponsored research by Licensor and its Investigators during the term of this Agreement will
not constitute a breach of this Agreement. All rights reserved to the U.S. Government under 35 U.S.C. §200 et. seq. and applicable
regulations shall remain so reserved and shall in no way be affected by this Agreement. Licensor and its Investigators are not
obligated under this Agreement to take any action which would conflict in any respect with their past, current or future obligations
to the U.S. Government as to work already performed and to be performed in the future.

 

		3.	Agreement Patents

 

		3.01	Licensor confirms that on the Original Effective Date, Licensee reimbursed Licensor for all costs incurred prior to the Original
Effective Date in connection with the preparation, filing, prosecution and maintenance of the Agreement Patents, which totaled
[***]. Amounts paid by Licensee pursuant to this paragraph are non-refundable and not creditable against any other payment due
to Licensor.

 

    	 	- 8 -	 

     

    

 

		3.02	Licensee and Licensor executed a joint representation engagement letter (“Engagement Letter”) dated March
5, 2015 with Amster, Rothstein & Ebenstein LLP, copy attached as Appendix B.

 

		3.03	As of and after the Original Effective Date, Licensee will pay the cost of preparing, filing, prosecuting, maintaining and
resisting challenges to the validity of the Agreement Patents (as well as the cost of preparing, filing, prosecuting, maintaining
and resisting challenges to the validity of corresponding applications in at least the United States, Europe (an EPO filing designating
all member countries), Canada, Japan and Australia). As part of this obligation, Licensee will pay the cost of applying for an
extension of the term of any patent included within Agreement Patents, if appropriate, under the Drug Price Competition and Patent
Term Restoration Act of 1984 and/or European, Japanese and other foreign counterparts. Licensee will pay the cost of defending
and/or prosecuting any interference, reexamination, reissue, opposition, cancellation and nullity proceedings involving Agreement
Patents. In the event that Licensee elects not to pay to maintain, defend or prosecute any patent or patent application within
the Agreement Patents, Licensee shall give Licensor thirty (30) days prior written notice of such election. Any patents or patent
applications so elected shall at the end of the notice period cease to be considered Agreement Patents, and Licensor shall then
be free, at its election, to abandon or maintain the prosecution of such patent application or issued patent or grant rights to
such patent application or issued patent to third parties. For purposes of this Agreement, “Developing Countries”
shall mean low and lower middle income countries as defined by the World Bank from time to time during the term of this Agreement.
Licensee agrees that any pharmaceutical product sold by Licensee and/or its Sublicensees in Developing Countries, other than India,
China and Brazil, shall be sold at a price equal to its cost to manufacture, distribute and/or sell the pharmaceutical product,
excluding research and development costs associated with developing the pharmaceutical product and obtaining regulatory approvals,
plus [***].

 

		3.04	Amounts paid by Licensee pursuant to Sections 3.01 and 3.03 will be non-refundable and not creditable against any other payment
due to Licensor.

 

    	 	- 9 -	 

     

    

 

		4.	License Grant

 

		4.01	Subject to Section 2, Licensor hereby grants to Licensee and Affiliates a worldwide, exclusive license, with the right by Licensee
only to grant sublicenses to unaffiliated third parties, under Licensor's rights in the Agreement Patents and Know-How to import,
make, have made, use, provide, offer to sell, and sell products, processes and services in the Field, namely, Licensed Products,
Know-How Products and MHC Class II Products. The terms of any sublicense agreement shall not contradict the terms of this Agreement
and shall include (at least) the following provisions: prohibiting any use of Licensor's name (consistent with Section 9.01), requiring
indemnification of Licensor (consistent with Section 12.04), and requiring appropriate insurance (consistent with Section 12.10),
and disclaiming any warranties or representations by Licensor (consistent with Sections 12.05 and 12.06). Licensee shall provide
Licensor with a full, unredacted and complete copy of any executed sublicense or amendment within thirty (30) days of execution
thereof by Licensee. Licensee may designate any such sublicense or amendment, in whole or in part, as Confidential Information.

 

		4.02	Notwithstanding the exclusive rights granted to Licensee pursuant to Section 4.01, Licensor shall retain the right to make,
use and practice, but not the right to license to third parties, Agreement Patents and Know-How in its own laboratories for research
purposes. Licensor shall also retain the right to make, use, and practice the inventions described in [***]. Further, Licensor
shall have the right to make available to not-for-profit scientific institutions and non-commercial researchers materials covered
under Agreement Patents and Know-How, solely for non-commercial scientific and research purposes.

 

		4.03	Nothing contained in this Agreement shall be construed or interpreted as a grant, by implication or otherwise, of any license
except as expressly specified in Section 4.01 hereof. The license granted herein shall apply to the Licensee and Affiliates except
that Affiliates shall not have the right to grant sublicenses. If any Affiliate exercises rights under this Agreement, Licensee
will promptly notify Licensor in writing, and such Affiliate shall be bound by all terms and conditions of this Agreement, including
but not limited to indemnity and insurance provisions, which shall apply to the exercise of the rights, to the same extent as would
apply had this Agreement been directly between Licensor and the Affiliate. In addition, Licensee shall remain fully liable to Licensor
for all acts and obligations of Affiliates such that acts of Affiliates shall be considered the acts of Licensee.

 

		5.	Confidentiality

 

		5.01	Nothing herein contained shall preclude Licensor from making required reports or disclosures to the NIH or to any other philanthropic
or governmental funding organization, provided, however, that no Confidential Information of Licensee is disclosed in the process.

 

    	 	- 10 -	 

     

    

 

		5.02	Licensee will retain in confidence Confidential Information of Licensor and Licensee will not disclose any such Confidential
Information to any third party without the prior written consent of Licensor, except that Licensee shall have the right to disclose
such information to any third party for commercial or research and development purposes under written terms of confidentiality
and non-disclosure which are commercially reasonable. These obligations of confidentiality are for a period ending five (5) years
after termination or expiration of this Agreement, provided, however, that such obligations shall not apply to any such information
which:

 

		(a)	was known to Licensee or generally known to the public prior to its disclosure hereunder as evidenced by written record; or

 

		(b)	subsequently becomes known to the public by some means other than a breach of this Agreement; or

 

		(c)	is subsequently disclosed to Licensee by a third party having a lawful right to make such disclosure; or

 

		(d)	is required to be disclosed by regulation, law or court order to the most limited extent necessary to comply therewith, provided
Licensor is given a fair opportunity to defend against such disclosure, and if disclosure is required, only discloses that portion
of the Confidential Information as is required; or

 

		(e)	is independently developed by Licensee as evidenced by Licensee's written records without reference to Licensor's Confidential
Information.

 

		5.03	Licensor will retain in confidence Confidential Information of Licensee and Licensor will not disclose any such Licensee Confidential
Information to any third party without the prior written consent of Licensee for a period ending five (5) years after termination
or expiration of this Agreement, provided however, that such obligations shall not apply to any such information which:

 

		(a)	was known to Licensor or generally known to the public prior to its disclosure hereunder as evidenced by written record; or

 

		(b)	subsequently becomes known to the public by some means other than a breach of this Agreement; or

 

		(c)	is subsequently disclosed to Licensor by a third party having a lawful right to make such disclosure; or

 

    	 	- 11 -	 

     

    

 

		(d)	is required to be disclosed by regulation, law or court order to the most limited extent necessary to comply therewith, provided
Licensee is given a fair opportunity to defend against such disclosure, and if disclosure is required, only discloses that portion
of the Confidential Information as is required; or

 

		(e)	is independently developed by Licensor as evidenced by Licensors written records without reference to Licensee’s Confidential
Information.

 

		6.	Royalties and Payments

 

		6.01	Licensee shall make the following payments to Licensor:

 

		(a)	Licensee will pay to Licensor:

 

		(i)	[***] of Net Sales on Licensed Products, provided, however, that this rate shall be reduced by [***] on a country-by-country
basis, if a Competing Product exists in such country.

 

		(ii)	[***] of Net Sales on MHC Class II Products, provided, however, that this rate shall be reduced to [***] on a country-by-country
basis, if a Competing Product exists in such country.

 

		(iii)	[***] of Net Sales on Know-How Products.

 

		(b)	Licensee will pay to Licensor a percentage of Net Proceeds as follows:

 

		(i)	[***] of Net Proceeds derived from agreements entered into before an Investigational New Drug application (IND) or foreign
equivalent is filed;

 

		(ii)	[***] of Net Proceeds derived from agreements entered into after an IND or foreign equivalent is filed but prior to the initiation
of a Phase II clinical trial or it foreign equivalent; and

 

		(iii)	[***] of Net Proceeds derived from agreements entered into after initiation of a Phase II clinical trial or its foreign equivalent.

 

		(c)	Licensee will pay to Licensor a percentage of Sublicensee Net Sales as follows:

 

		(i)	The greater of [***] of the royalty received by Licensee from a Sublicensee based on the sale of a Sublicensee Product or [***]
of Sublicensee Net Sales for such Sublicensee Product, derived from agreements entered into before an IND is filed;

 

    	 	- 12 -	 

     

    

 

		(ii)	The greater of [***] of the royalty received by Licensee from a Sublicensee based on the sale of a Sublicensee Product or [***]
of Sublicensee Net Sales for such Sublicensee Product, derived from agreements entered into after an IND but prior to Phase II;
and

 

		(iii)	The greater of [***] of the royalty received by Licensee from a Sublicensee based on the sale of a Sublicensee Product or [***]
of Sublicensee Net Sales for such Sublicensee Product, derived from agreements entered into after initiation of a Phase II clinical
trial.

 

		6.02	Licensee has made or shall make the following license signing and license maintenance payments to Licensor:

 

		(a)	Licensee has paid Licensor a total of [***] as a license signing fee which payment is non-refundable and not creditable against
any other payment due to Licensor pursuant to this Agreement.

 

		(b)	On the second anniversary of the Original Effective Date, Licensee paid to Licensor Twenty-Five Thousand Dollars (US$25,000) as a license maintenance fee. This
fee is non-refundable but is creditable against actual payments due to Licensor pursuant to Section 6.01 during the twelve (12)
month period following this anniversary.

 

		(c)	On the third and fourth anniversaries of the Original Effective Date, Licensee will pay to Licensor Fifty Thousand Dollars (US$50,000) as a license maintenance
fee. Each such fee is non-refundable but is creditable against actual payments due to Licensor pursuant to Section 6.01 during
the twelve (12) month period following each such anniversary.

 

		(d)	On the fifth and sixth anniversary of the Original Effective Date, Licensee will pay to Licensor Seventy-Five Thousand Dollars (US$75,000) as a license maintenance
fee. Each such fee is non-refundable but is creditable against actual payments due to Licensor pursuant to Section 6.01 during
the twelve (12) month period following each such anniversary.

 

		(e)	On the seventh anniversary of the Original Effective Date and every anniversary of the Original Effective Date thereafter,
Licensee will pay to Licensor One Hundred Thousand Dollars (US$100,000) as a license maintenance fee. Each such fee is non-refundable but is creditable against actual
payments due to Licensor pursuant to Section 6.01 during the twelve (12) month period following each such anniversary.

 

    	 	- 13 -	 

     

    

 

		6.03	Licensee shall make the following milestone payments to Licensor for Licensed Products:

 

		(a)	Upon approval of the first Investigational New Drug (IND) application (or its foreign equivalent) by, on behalf of or for the
benefit of Licensee or an Affiliate, for a Licensed Product anywhere in the world, Licensee shall pay to Licensor a fee of [***];

 

		(b)	Upon approval of the first Investigational New Drug (IND) application (or its foreign equivalent) by, on behalf of or for the
benefit of Licensee or an Affiliate, for a new indication for a Licensed Product anywhere in the world, Licensee shall pay to Licensor
a fee of [***];

 

		(c)	Upon the initiation by, on behalf of or for the benefit of Licensee or an Affiliate, of the first Phase II clinical trial (or
its foreign equivalent) for a Licensed Product anywhere in the world, Licensee shall pay to Licensor a fee of [***];

 

		(d)	Upon the initiation by, on behalf of or for the benefit of Licensee or an Affiliate, of the first Phase II clinical trial (or
its foreign equivalent) for a new indication for a Licensed Product anywhere in the world, Licensee shall pay to Licensor a fee
of [***];

 

		(e)	Upon the initiation by, on behalf of or for the benefit of Licensee or an Affiliate, of the first Phase Ill clinical trial
(or its foreign equivalent) for a Licensed Product anywhere in the world, Licensee shall pay to Licensor a fee of [***]; and

 

		(f)	Upon the initiation by, on behalf of or for the benefit of Licensee or an Affiliate, of the first Phase III clinical trial
(or its foreign equivalent) for a new indication for a Licensed Product anywhere in the world, Licensee shall pay to Licensor a
fee of [***];

 

		(g)	Upon first commercial sale by, on behalf of or for the benefit of Licensee or an Affiliate of a Licensed Product anywhere in
the world, Licensee shall pay to Licensor [***].

 

		(h)	Upon first commercial sale by, on behalf of or for the benefit of Licensee or an Affiliate of a Licensed Product having a new
indication anywhere in the world, Licensee shall pay to Licensor [***].

 

    	 	- 14 -	 

     

    

 

		(i)	When the cumulative sales of Licensed Products from a sublicensing agreement reach [***], Licensee shall pay to Licensor Five Million Dollars (US$5,000,000).

 

		(j)	Licensee shall pay to Licensor a one-time success-based milestone of (i) [***] when the cumulative sales of Licensed Products
and/or MHC Class II Products developed in whole or in part with Contract Research received prior to the [***] of the Restated Agreement
Effective Date, reach [***] (“the LP/MHC Milestone”) or (ii) [***] when the cumulative sales of Know-How Products
developed in whole or in part with Contract Research received prior to the [***] of the Restated Agreement Effective Date, reach
[***] (“the KH Milestone”), whichever occurs first. If Licensee pays the KH Milestone first, and then the LP/MHC
Milestone is achieved thereafter, then Licensee shall pay Licensor an additional [***].

 

Payments made pursuant to Sections (a) through (j)
are non-refundable and not creditable against any other payment due to Licensor.

 

		6.04	Only one royalty will be payable on Net Sales by Licensee and Affiliates on a Licensed Product or MHC Class II Product under
Section 6.01, regardless of the number of Valid Claims in Agreement Patents which cover such Licensed Product or MHC Class II Product.
If Licensee or any Affiliate is required, because of the patent rights of any third party or parties, to pay royalties to a third
party or parties in order to make, use or sell a specific Licensed Product or MHC Class II Product, then Licensee may deduct [***]
of all such royalties paid to such third party or parties from up to [***] of the royalty due to Licensor on such specific Licensed
Product or MHC Class II Product pursuant to Section 6.01. In no event will the royalty payable to Licensor on any Licensed Product
or MHC Class II Product be reduced below [***] pursuant to this Section 6.04 and/or Section 6.01. The royalty stacking provision
of this Section 6.04 does not apply to Know-How Products.

 

		6.05	Immediately prior to the consummation of a Liquidity Event, Licensee shall issue to Licensor shares of Licensee’s Common
Stock (the “Shares”) such that, following the issuance of the Shares, Licensor will own:

 

		(a)	if the Liquidity Event is consummated before achievement of the Funding Threshold, a number of shares of Licensee’s Common
Stock equal to [***] of Licensee’s capital stock following such issuance calculated on a Fully Diluted, as Converted Basis,
and

 

		(b)	if the Liquidity Event is consummated after achievement of the Funding Threshold, a number of shares of Licensee’s Common
Stock equal to [***] of Licensee’s capital stock following such issuance calculated on a Fully Diluted, as Converted Basis
as of the date and time such Funding Threshold was met (subject to adjustment for any stock dividends, stock splits, reverse splits
or similar recapitalizations occurring thereafter).

 

    	 	- 15 -	 

     

    

 

If the Liquidity Event is a Going Public Event, Licensee
will use its best efforts to (i) file a registration statement covering the resale of the Shares as soon as practicable but no
later than one hundred eighty (180) calendar days from the date of the Liquidity Event and (ii) cause such registration statement
to be declared effective within 120 calendar days from the date of issuance.

 

		6.06	Licensor hereby agrees that, (a) to the extent requested by Licensee and any managing underwriter retained by Licensee, Licensor
will not directly or indirectly sell, offer to sell, contract to sell (including without limitation, any short sale), grant any
option to purchase, pledge or otherwise transfer or dispose of (other than to donees who agree to be similarly bound), during the
period of duration (not to exceed twelve (12) months) specified by Licensee and Licensee’s managing underwriter following
the effective date of the registration statement of Licensee filed under the Securities Act with respect to Licensee’s initial
public offering, any securities of Licensee held by Licensor at any time during such period except Common Stock included in such
registration and (b) if requested by such underwriter, Licensor agrees to execute a lock-up agreement in such form as the managing
underwriter may reasonably propose; provided that, in each case Licensor’s obligations under this subsection are conditioned
upon all of Licensee’s other founders being subject to identical obligations. Furthermore, in the event that the Shares are
registered under Section 5 of the Securities Act, or become eligible for sale without registration under SEC Rule 144, Licensor
agrees to abide by the volume limitations applicable to an “affiliate” under SEC Rule 144, unless the Licensee or the
Licensee's managing underwriter agrees otherwise. Notwithstanding the foregoing, the registration rights provided for in this Section
6.05 shall terminate on the date that the Shares may be sold without registration under SEC Rule 144.Licensee’s failure to
pay full royalties or make complete payments under Sections 6.01, 6.02 or 6.03 or to comply with its obligations under Section
6.05 shall be a breach of this Agreement if not cured within forty-five (45) days of Licensee’s receipt of written notice
of such failure.

 

		7.	Payment Reports and Records

 

		7.01	All payments required to be made by Licensee to Licensor pursuant to this Agreement shall be made to Licensor in U.S. Dollars
by wire transfer or by check payable to Licensor and sent to Licensor’s address set out in Section 13.01.

 

    	 	- 16 -	 

     

    

 

		7.02	All payments required to be made by Licensee to Licensor pursuant to this Agreement shall be subject to a charge of One and
One-Half Percent (1.5%) per month or Two Hundred and Fifty Dollars (US$250), whichever is greater, if more than 30 days late. Conversion
of foreign currency to U.S. dollars shall be made at the conversion rate quoted by the Wall Street Journal, averaged on the last
business day of each of the three (3) consecutive calendar months constituting the calendar quarter in which the payment was earned.
Licensee will bear any loss of exchange or value and pay any expenses incurred in the transfer or conversion to U.S. dollars.

 

		7.03	Payments due from Licensee to Licensor pursuant to Section 6.01 will be paid within thirty (30) days after the end of each
calendar year quarter during which the payment accrued. If no payments pursuant to Section 6.01 are due for any quarter, Licensee
shall send to Licensor a statement to that effect signed by an officer of Licensee. Payment shall be accompanied by a statement
of the number of Licensed Products, Know-How Products, MHC Class II Products and Combination Products sold by Licensee, Affiliates
and Sublicensees in each country, total billings for such Licensed Products, Know-How Products, MHC Class II Products and Combination
Products, the values of A and B used to calculate the Net Sales and Sublicensee Net Sales of Combination Products, deductions applicable
to determine the Net Sales and Sublicensee Net Sales thereof, the amount of Net Sales and Sublicensee Net Sales realized by Licensee
and Affiliates and Sublicensees, the amount of Net Proceeds realized by Licensee, the amount of any deduction and a detailed listing
thereof, and the total payment due from Licensee to Licensor (the "Royalty Report"). Such Royalty Report shall
be signed by an officer of Licensee.

 

		7.04	Licensee and Affiliates shall maintain complete and accurate books of account and records showing Net Sales, Sublicensee Net
Sales and Net Proceeds. Such books and records of Licensee and Affiliates shall be open to inspection, in confidence, during usual
business hours, upon at least ten (10) business days prior notice to Licensee, by an independent certified public accountant appointed
by Licensor on behalf of Licensor, who has entered into a written agreement of confidentiality with Licensor which is no less protective
of Licensee’s Confidential Information than the provisions of Section 5.03 hereof and to whom Licensee has no reasonable
objection, for five (5) years after the calendar year to which they pertain, for the purpose of verifying the accuracy of the payments
made to Licensor by Licensee pursuant to this Agreement. Licensee will use commercially reasonable efforts to require any Sublicensees
hereunder to maintain such books and allow such inspection by licensee and shall, on request, disclose such information, if available
to Licensee, to Licensor as part of such inspection. Inspection shall be at Licensor’s sole expense and reasonably limited
to those matters related to Licensee’s payment obligations under this Agreement and shall take place not more than once per
calendar year. Any underpayment revealed by any inspection, plus interest on the underpayment amount at the rate of One and One-Half
Percent (1.5%) per month or Two Hundred Fifty Dollars (US$250), whichever is greater, shall be promptly paid by Licensee to Licensor.
Further, if any inspection reveals an underpayment to Licensor of Ten Percent (10%) or greater, then the cost of the inspection
shall be paid by Licensee.

 

    	 	- 17 -	 

     

    

 

		8.	Infringement

 

		8.01	Licensee shall have the right, in its sole discretion and its expense, to initiate legal proceedings on its behalf or in Licenser’s
name, if necessary, against any infringer, or potential infringer, of an Agreement Patent who imports, makes, uses, sells or offers
to sell products in the Field. Licensee shall notify Licensor of its intention to initiate such proceedings at least thirty (30)
days prior to commencement thereof. Any settlement or recovery received from any such proceeding shall be divided [***] to Licensee
and [***] to Licensor after Licensee deducts from any such settlement or recovery its actual counsel fees and out-of-pocket expenses
relating to any such legal proceeding. If Licensee decides not to initiate legal proceedings against any such infringer, Licensee
shall notify Licensor in writing of such decision, then Licensor shall have the right to initiate such legal proceedings. Any settlement
or recovery received from any such proceeding initiated by Licensor shall be divided [***] to Licensor and [***] to Licensee after
Licensor deducts from any such settlement or recovery its actual counsel fees and out-of-pocket expenses relating to any such legal
proceeding.

 

		8.02	In the event that either party initiates or carries on legal proceedings to enforce any Agreement Patent against an alleged
infringer, the other party shall fully cooperate with and supply all assistance reasonably requested at the expense of the party
requesting such assistance. Further, the other party, at its expense, shall have the right to be represented by counsel of its
choice in any such proceeding, However, if Licensee initiates legal proceedings in Licensor's name, Licensee shall reimburse Licensor
for any reasonable out of pocket counsel fees of Licensor associated with the legal proceedings. The party who initiates or carries
on the legal proceedings shall have the sole right to conduct such proceedings provided, however, that such party shall consult
with the other party to this Agreement prior to entering into any settlement thereof.

 

    	 	- 18 -	 

     

    

 

		9.	Prohibition on Use of Names: No Publicity

 

		9.01	Neither party to this Agreement shall use the name of the other party without the other party's prior written consent, except
if the use of such name is required by law, regulation, federal securities law, or judicial order, in which event the party intending
to make such announcement will promptly inform the other party, prior to any such required use. Neither party to this Agreement
will make any public announcement regarding the existence of this Agreement and/or the collaboration hereunder without obtaining
the prior written consent of the other party, except if such announcement is required by law, regulation, federal securities law
or judicial order, in which event the party intending to make such announcement will promptly inform the other party prior to any
such required announcement.

 

		10.	Term and Termination

 

		10.01	Unless terminated earlier
                                         under other provisions hereof, this Agreement will expire upon the expiration of Licensee's
                                         last obligation to pay royalties on Net Sales and/or Net Proceeds and/or Sublicensee
                                         Net Sales to Licensor pursuant to Section 6.01. Royalties on Net Sales for Know-How Products
                                         shall be due for the longer of fifteen (15) years from first sale of such product
                                         in each country or for the duration of any market exclusivity period granted by a regulatory
                                         agency for such product. Royalties on Sublicensee Net Sales for Know-How Products shall
                                         be due for the longer of ten (10) years from first sale of such product in each
                                         country or for so long as the Sublicensee agrees to pay such royalties. Upon termination
                                         or expiration of this Agreement for any reason, Section 1, 5, 6.05, 7, 8, 9, 10.07 through
                                         10.09, 11, 12.01 through 12.10, 12.13, 12.16 and 13 shall survive and all payment obligations
                                         under Sections 3 and 6.01-6.04 hereof accrued as of the termination date shall be paid
                                         by Licensee within thirty (30) days of such termination or expiration.

 

		10.02	Licensee may terminate this Agreement and the licenses granted hereunder by giving notice to Licensor sixty (60) days prior
to such termination. Upon such termination, Licensee shall not use Agreement Patents or Know-How for any purpose and all of Licensee's
rights in Agreement Patents and Know-How shall be terminated.

 

    	 	- 19 -	 

     

    

 

		10.03	If either Licensor or Licensee defaults on or breaches any condition of this Agreement, the aggrieved party may serve notice
upon the other party of the alleged default or breach, which notice shall state with particularity the alleged breach. If such
default or breach is not remedied within sixty (60) days from the date of such notice and the alleged breaching party has not requested
the alternative dispute resolution procedure set forth below, then the aggrieved party may at its election terminate this Agreement
by providing fifteen (15) days written notice. Any failure to terminate hereunder shall not be construed as a waiver by the aggrieved
party of its right to terminate for future defaults or breaches. Licensee's damages for any breach of this Agreement by Licensor
will be limited to the amount paid by Licensee to Licensor under this Agreement and a reduction or suspension of the payment obligations
of Licensee hereunder Upon termination of this Agreement by Licensor pursuant to this Section 10.03, the licenses granted by Licensor
to Licensee shall terminate and Licensee shall not use Agreement Patents or Know-How for any purpose and all of Licensee's rights
in Agreement Patents and Know-How shall be terminated.

 

In the event that, within thirty (30) days from the
date of a notice of breach, the alleged breaching party (1) disputes in good faith the alleged breach, (ii) provides a detailed
explanation of why it believes the alleged breach has not occurred, and (iii) requests alternative dispute resolution, then the
party representatives, e.g., CEO of Cue and Director, Office of Biotechnology, with authority to settle the dispute shall meet
within thirty (30) days at a mutually agreeable time and place and attempt in good faith to amicably resolve the dispute. If the
parties fail to resolve the dispute through such meeting, then the aggrieved party may at its election terminate this Agreement
by providing fifteen (15) days written notice.

 

		10.04	This Agreement sets forth a license to intellectual property rights. To the extent permitted by applicable law (including,
but not limited to, 11 U.S.C. Section 365) either party may terminate this Agreement immediately by written notice to the other
upon (i) the institution by such party of insolvency, receivership or bankruptcy proceedings or any other act of bankruptcy or
proceedings for the settlement of its debts; (ii) the institution of such proceedings against such party, which is not dismissed
or otherwise resolved in its favor within ninety (90) days thereafter; or (iii) such party making a general assignment for the
benefit of creditors.

 

		10.05	If Licensee is convicted of a felony under the Federal Food, Drug and Cosmetic Act, as amended from time to time, relating
to the manufacture, use or sale of Licensed Products, Know-How Products and/or MHC Class II Products or a felony involving moral
turpitude relating to the manufacture, use or sale of Licensed Products, Know-How Products and/or MHC Class II Products, Licensor
may, at its election, terminate this Agreement by notice to Licensee. Upon termination of this Agreement by Licensor pursuant to
this Section 10.05, the licenses granted by Licensor to Licensee shall terminate and Licensee shall not use Agreement Patents or
Know-How for any purpose and all of Licensee’s rights in Agreement Patents shall be terminated, provided that Licensee shall
have the right to sell off existing inventory of Licensed Products, Know-How Products and MHC Class II Products for up to sixty
(60) days following such termination.

 

    	 	- 20 -	 

     

    

 

		10.06	Notwithstanding the provisions of Section 10.03 hereof, should Licensee fail to pay Licensor any sum due and payable under
this Agreement on thirty (30) days written notice, Licensor may, at its election, terminate this Agreement, unless Licensee pays
Licensor within forty-five (45) days of notice of non-payment all delinquent sums together with interest due and unpaid. Upon termination
of this Agreement by Licensor pursuant to this Section 10.06, the licenses granted by Licensor to Licensee shall terminate and
Licensee shall not use Agreement Patents or Know-How for any purpose and all of Licensee’s rights in Agreement Patents and
Know-How shall be terminated.

 

		10.07	Termination of this Agreement by Licensee or Licensor shall not prejudice the rights of either party accruing herein. Notwithstanding
any provision herein to the contrary, no termination of this Agreement shall be construed as a termination of any valid sublicense
of any Sublicensee hereunder, and thereafter each such Sublicensee shall be considered a direct licensee of Licensor, provided
that (i) such Sublicensee is not in material breach of its sublicense agreement with Licensee, and (ii) such Sublicensee agrees
in writing to assume all applicable obligations of Licensee under this Agreement.

 

    	 	- 21 -	 

     

    

 

		10.08	If Licensee terminates this Agreement pursuant to Section 10.02, or if Licensor terminates this Agreement pursuant to Sections
10.03, 10.04, 10.05 or 10.06 of this Agreement, and if no sublicenses granted pursuant to Section 4.01 are in effect at the time
of such termination, then Licensee shall, upon such termination, grant a royalty-free, non-exclusive license to Licensor in and
to any Dependent Patents and Dependent Know-How (as defined below) developed by or for Licensee or Affiliates during the term of
this Agreement for no additional consideration, and shall, within thirty (30) days of termination, provide copies of all documents
and other materials embodying Dependent Know-How to Licensor. As used in this Section 10.08, the term "Dependent Patents"
means any U.S. or foreign patent application or patent which claims an invention the practice of which would infringe a claim of
a patent or patent application of the Agreement Patents or the practice of which results in a product covered by a claim of a patent
or patent application of Agreement Patents. "Dependent Know-How" means confidential information, including clinical
trial information, the practical application of which would infringe a claim of a patent or patent application of Agreement Patents,
or which results in a product covered by a claim of a patent or patent application of Agreement Patents. Licensee agrees to take
all actions and execute any and all documents reasonably requested by Licensor to effectuate the terms of this Section 10.08. During
the time period between notice of termination and the effective date of termination, Licensee will take whatever actions are necessary
to prevent any Dependent Patent from becoming abandoned or canceled. If Licensee terminates this Agreement pursuant to Section
10.02, or if Licensor terminates this Agreement pursuant to Sections 10.03, 10.04, 10.05 or 10.06 of this Agreement, and if no
sublicenses granted pursuant to Section 4.01 are in effect at the time of such termination, then Licensee shall also grant Licensor
(and/or Licensor's designee) a right of reference with respect to any investigation performed by or on behalf of Licensee in connection
with the Agreement - i.e., the authority to rely upon and otherwise use said investigation for the purpose of obtaining FDA approval
of an application for marketing clearance and/or approval, including without limitation, the ability to make available the underlying
raw data from the investigation for FDA audit, if necessary. In the event that one or more sublicenses granted pursuant to Section
4,01 are in effect at the time of such termination, then Licensor shall receive no rights in and to any such Dependent Patents
and Dependent Know-How, right of reference, or any other property of Licensee for as long as any direct license(s) between Licensor
and such sublicensee(s) provided in Section 10.07 remain in effect. If Licensee terminates this Agreement pursuant to Section 10.02,
or if Licensor terminates this Agreement pursuant to Sections 10.03, 10.04, 10.05 or 10.06 of this Agreement, and sublicenses granted
pursuant to Section 4.01 are in effect at the time of such termination, then the provisions of this paragraph shall be stayed for
the duration of the sublicenses, provided however, that such sublicensees have licenses under Dependent Patents and Dependent Know-How
from Licensee.

  

		10.09	If Licensee terminates this Agreement pursuant to Section 10.02 or 10.03, or if Licensor terminates this Agreement pursuant
to Sections 10.03, 10.04, 10.05 or 10.06 of this Agreement, Licensee shall submit a final Royalty Report to Licensor and any payments
and patent costs due to Licensor hereunder as of the date of termination shall be payable within thirty (30) days of the date of
termination. In addition, within ten (10) days of notice of such termination, Licensee shall provide Licensor with a report showing
the status of all Dependent Patents, including, without limitation, a list of all countries where Dependent Patents have been filed
and a list of all actions which must be taken with respect to the Dependent Patents and relevant due dates.

 

    	 	- 22 -	 

     

    

 

		11.	Amendment and Assignment

 

		11.01	This Agreement sets forth the entire understanding between the parties pertaining to the subject matter hereof and supersedes
and replaces all prior agreements between the parties, including, without limitation, the Original License.

 

		11.02	Except as otherwise provided herein, this Agreement may not be amended, supplemented or otherwise modified, except by an instrument
in writing signed by all parties.

 

		11.03	Without the prior written approval of the other party, which approval shall not be unreasonably withheld, no party may assign
this Agreement except that this Agreement may be assigned to an entity acquiring substantially all of such party’s business
to which this Agreement relates, or in the event of a merger, consolidation, change in control or similar transaction of such party.
Any attempted assignment in contravention of this Section 11.03 shall be null and void.

 

		12.	Miscellaneous Provisions

 

		12.01	This Agreement shall be construed and the rights of the parties governed in accordance with the laws of the State of New York,
excluding its law of conflict of laws. Any dispute or issue arising hereunder, including any alleged breach by any party, shall
be heard, determined and resolved by an action commenced first in federal courts in New York, New York, which the parties hereby
agree shall have proper jurisdiction and venue over the issues and the parties or in the state courts in New York, New York, only
if the federal courts do not have subject matter jurisdiction. Licensor and Licensee hereby agree to submit to the jurisdiction
of the state or federal courts in New York and waive the right to make any objection based on jurisdiction or venue. The New York
courts shall have the right to grant all relief to which Licensor and Licensee are or shall be entitled hereunder, including all
equitable relief as the Court may deem appropriate.

 

		12.02	This Agreement has been prepared jointly.

 

		12.03	If any term or provision of this Agreement or the application thereof to any person or circumstance shall to any extent be
invalid or unenforceable, the remainder of this Agreement or the application of such term or provision to persons or circumstances
other than those as to which it is held invalid or unenforceable shall not be affected thereby and each term and provision of this
Agreement shall be valid and enforced to the fullest extent permitted by law.

 

    	 	- 23 -	 

     

    

 

		12.04	Licensee agrees to indemnify Licensor and its current or former directors, governing board members, trustees, officers, faculty,
medical and professional staff, employees, students and agents and their respective successors, heirs and assigns (Licensor and
each such person being the "Indemnified Parties") for the cost of defense and for damages awarded and losses and
liabilities incurred, if any, as a result of any third party claims, liabilities, suits or judgments based on or arising out of
the research, development, marketing, manufacture, sale and/or provision of Licensed Products, Know-How Products and/or MHC Class
II Products by Licensee, Affiliates and Sublicensees, and/or the licenses granted under this Agreement, or otherwise related to
the conduct of Licensee’s, Affiliates’ or Sublicensees’ business, so long as such claims, liabilities, suits,
or judgments are not solely attributable to grossly negligent or intentionally wrongful acts or omissions by the Indemnified Parties.
This indemnity is conditioned upon Licensor’s obligation to: (i) advise Licensee of any claim or lawsuit, in writing promptly
after Licensor or the Indemnified Party has received notice of said claim or lawsuit, (ii) assist Licensee and its representatives,
at Licensee’s expense, in the investigation and defense of any lawsuit and/or claim for which indemnification is provided,
and (iii) permit Licensee to control the defense of such claim or lawsuit for which indemnification is provided.

 

		12.05	Nothing in this Agreement is or shall be construed as:

 

		(a)	A warranty or representation by Licensor that anything made or used by Licensee under any license granted in this Agreement
is or will be free from infringement of patents, copyrights, and other rights of third parties; or

 

		(b)	Granting by implication, estoppel, or otherwise any license, right or interest other than as expressly set forth herein.

 

		12.06	Except as expressly set forth in this Agreement, the parties MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND,
EITHER EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, STATUTE OR OTHERWISE, AND THE PARTIES SPECIFICALLY DISCLAIM ANY
IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR WARRANTY OF NON-INFRINGEMENT. IN ADDITION, NEITHER
PARTY SHALL BE LIABLE FOR ANY SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY
AND WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

 

    	 	- 24 -	 

     

    

 

		12.07	Licensor and Licensee represent and warrant that, to the best of their knowledge, as of the Original Effective Date:

 

		(a)	they have the legal right and authority to enter into this Agreement and to perform all of their obligations hereunder;

 

		(b)	when executed by all parties, this Agreement will constitute a valid and legally binding obligation and shall be enforceable
in accordance with its terms; and

 

		(c)	there are no existing or threatened actions, suits or claims pending or threatened against it that may affect the performance
of its obligations under the Agreement.

 

		12.08	Licensor represents and warrants that:

 

		(a)	Licensor owns all right, title and interest in, to and under the Agreement Patents by virtue of assignment from the Investigators;

 

		(b)	Licensor has the legal power and authority to extend the rights granted to Licensee in this Agreement;

 

		(c)	Subject to the rights, if any, of the U.S. government, Licensor has not conveyed or transferred any intellectual property rights
under the Agreement Patents to any person other than Licensee.

 

		(d)	to the best of Licensor’s knowledge, as of the Original Effective Date, subject to any rights of the government as discussed
in Section 2.01, the Agreement Patents are free and clear of all liens and encumbrances; and

 

		(e)	other than U.S. Patent Application No. 13/085,081, as of the Original Effective Date, Licensor’s Investigator, Steven
C. Almo is not listed as an inventor on any patents or patent applications or “invention disclosures” by Mr. Almo made
to Licensor relevant to the subject matter disclosed and claimed in the Agreement Patents.

 

		12.09	Licensee represents and warrants that it has not relied on any information provided by Licensor, Licensor’s current or
former employees or the Investigators and has conducted its own due diligence investigation to its satisfaction prior to entering
into this Agreement.

 

    	 	- 25 -	 

     

    

 

		12.10	Licensee represents and warrants that before Licensee, or an Affiliate or a Sublicensee makes any sales of Licensed Products,
Know-How Products and/or MHC Class II Products or performs or causes any third party to perform any clinical trials or tests in
human subjects involving Licensed Products, Know-How Products and/or MHC Class II Products, Licensee or Affiliates or Sublicensees
will acquire and maintain in each country in which Licensee or Affiliates or Sublicensees shall test or sell Licensed Products,
Know-How Products and/or MHC Class II Products, appropriate insurance coverage reasonably acceptable to Licensor, but providing
coverage in respect of Licensed Products, Know-How Products and MHC Class II Products in an amount no less than [***] per claim
and [***] in the aggregate for all claims. Licensee or Affiliates will not perform, or cause any third party to perform, any clinical
trials or any tests in human subjects involving Licensed Products, Know-How Products and/or MHC Class II Products unless and until
it obtains all required regulatory approvals with respect to Licensed Products, Know-How Products and/or MHC Class II Products
in the applicable countries. Prior to instituting any clinical trials or any tests in human subjects, or sale of any Licensed Product,
Know-How Product and/or WIC Class II Product, Licensee shall provide evidence of such insurance to Licensor. If Licensor determines
that such insurance is not reasonably appropriate, it shall so advise Licensee and Licensee shall delay such trials, tests or sales
until the parties mutually agree that reasonably appropriate coverage is in place. Licensor shall be listed as an additional insured
in Licensee’s insurance policies. If such insurance is underwritten on a ‘claims made’ basis, Licensee agrees
that any change in underwriters during the term of this Agreement will require the purchase of 'prior acts' coverage to ensure
that coverage will be continuous throughout the term of this Agreement.

 

		(a)	The minimum amounts of insurance coverage required under this Section shall not be construed to create a limit of Licensee's
liability with respect to its indemnification under Section 12.04 of this Agreement.

 

		(b)	Licensee shall provide Licensor with written evidence of such insurance upon request of Licensor. Licensee shall provide Licensor
with written notice at least sixty (60) days prior to the cancellation, non-renewal or material change in such insurance; if Licensee
does not obtain replacement insurance providing comparable coverage within such sixty (60) day period, Licensor shall have the
right to terminate this Agreement effective at the end of such sixty (60) day period without notice or any additional waiting periods.

 

		(c)	Licensee shall maintain such comprehensive general liability insurance beyond the expiration or termination of this Agreement
during (I) the period that any product, process or service, relating to, or developed pursuant to, this Agreement is being commercially
distributed or sold or tested in clinical trials by Licensee or by a Sublicensee, Affiliate, optionee or agent of Licensee and
(ii) a reasonable period after the period referred to in (i) above which in no event shall be less than fifteen (15) years.

 

    	 	- 26 -	 

     

    

 

		12.11	Licensee shall exercise its rights and perform its obligations hereunder in compliance with all applicable laws and regulations.
In particular, it is understood and acknowledged that the transfer of certain commodities and technical data is subject to United
States laws and regulations controlling the export of such commodities and technical data, including all Export Administration
Regulations of the United States Department of Commerce. These laws and regulations, among other things, prohibit or require a
license for the export of certain types of technical data to certain specified countries. Licensee hereby agrees and gives written
assurance that it will comply with all United States laws and regulations controlling the export of commodities and technical data,
that it will be solely responsible for any violation of such by Licensee or Affiliates or Sublicensees, and that it will defend
and hold Licensor harmless in the event of any legal action of any nature occasioned by such violation.

 

		12.12	Licensee agrees (i) to obtain all regulatory approvals required for the manufacture and sale of Licensed Products, Know-How
Products and MHC Class II Products prior to marketing or selling any such Licensed Products, Know-How Products and/or MHC Class
II Products and (ii) to utilize legally appropriate patent marking on such Licensed Products. Licensee agrees to register or record
this Agreement as is required by law or regulation in any country where the license is in effect.

 

		12.13	Licensee agrees that any Licensed Products for use or sale in the United States will be manufactured substantially in the United
States.

 

		12.14	Any tax required to be withheld under the laws of any jurisdiction on royalties payable to Licensor by Licensee under this
Agreement will be promptly paid by Licensee for and on behalf of Licensor to the appropriate governmental authority, and Licensee
will furnish Licensor with proof of payment of the tax together with official or other appropriate evidence issued by the competent
governmental authority sufficient to enable Licensor to support a claim for tax credit with respect to any sum so withheld. Any
tax required to be withheld on payments by Licensee to Licensor will be an expense of and be borne solely by Licensor, and Licensee’s
royalty payment(s) to Licensor following the withholding of the tax will be decreased by the amount of such tax withholding. Licensee
will cooperate with Licensor in the event Licensor elects to assert, at its own expense, exemption from any tax.

 

    	 	- 27 -	 

     

    

 

		12.15	Licensee, by itself or through an Affiliate or Sublicensee, will meet all of the following due diligence requirements:

 

		(a)	Provide a research and development plan within forty-five (45) days of signing and update the research and development plan
annually. Each update shall include not only a research and development plan for the upcoming twelve (12) months, but also, a summary
of the activity for the past twelve months, including (i) all research and development; (ii) all fundraising efforts and the results
of those efforts; and (iii) all diligence requirements and milestones achieved; and;

 

		(b)	Submit an investigational new drug application to the FDA for a Licensed Product within [***] of the Original Effective Date;
and

 

		(c)	Initiate an FDA approved Phase I clinical trial for a Licensed Product within [***] of the Original Effective Date; and

 

		(d)	Initiate an FDA approved Phase II clinical trial for a Licensed Product within [***] of the Original Effective Date; and

 

		(e)	Initiate an FDA approved Phase Ill clinical trial for a Licensed Product within [***] of the Original Effective Date.

 

		(f)	Submit an application for FDA approval to market and sell a Licensed Product within [***] of the Original Effective Date;

 

		(g)	Have a first commercial sale of a Licensed Product within [***] of the Original Effective Date.

 

		(h)	Spend a minimum of Two Hundred and Fifty Thousand Dollars (US$250,000) per year on product development until the first commercial sale of the first Licensed Product.

 

		12.16	Licensee shall have raised the following aggregate amounts in cash from the sale of its capital stock and Convertible Securities
on or before the dates set forth below.

 

		(a)	[***] by the first anniversary of the Original Effective Date;

 

		(b)	[***] by the third anniversary of the Original Effective Date; and

 

		(c)	[***] by the fifth anniversary of the Original Effective Date.

 

    	 	- 28 -	 

     

    

 

		12.17	If any one of the due diligence requirements in Section 12.15 and/or 12.16 is not met, Licensor shall have the right to terminate
pursuant to Section 10.03 and all rights will revert to Licensor, after providing Licensee with written notice of failure to meet
such requirements and thirty (30) days from the date of such written notice to cure such failure. Notwithstanding the foregoing,
in the event that Licensee provides Licensor with prior written notice that Licensee, despite its best efforts, is unable to fulfill
the due diligence requirement for Section 12.16(d), (e), (f), (g) and/or (h), the deadline for fulfilling such requirement shall
be extended by [***]. No further extensions shall be granted for such diligence requirement without Einstein’s prior written
consent. In the event Licensee is unable to fulfill a due diligence requirement for Section 12.16(d), (e), (f), (g) or (h) after
an extension has been granted, Licensor shall have the right to terminate pursuant to Section 10.03 and all rights will revert
to Licensor, after providing Licensee with written notice of failure to meet such requirements and thirty (30) days from the date
of such written notice to cure such failure.

 

		12.18	In the event Licensee (or any entity acting under Licensee’s control or on its behalf) initiates any proceeding or otherwise
asserts any claim challenging the validity or enforceability of a claim of an Agreement Patent in any court, administrative agency
or other forum other than as a defense to an action initiated by the Licensor (“Challenge”), the royalty rates
set forth in Section 6.01 and the license maintenance fees set forth in Section 6.02 shall increase by [***] during the pendency
of such Challenge. Should the outcome of such Challenge determine that any challenged claim of an Agreement Patent is valid, Licensee
(i) shall thereafter, and for the remaining term of this Agreement, continue to pay the royalty rate set forth in Section 6.01
and the license maintenance fees set forth in Section 6.02 increased by [***]; and (ii) agrees to pay all costs and expenses (including
actual outside attorneys' fees) incurred by Licensor in connection with defending the Challenge. Should the outcome of such Challenge
determine that the challenged claim or claims of an Agreement Patent are invalid, Licensor shall be responsible for paying its
own costs and expenses in connection with defending the Challenge and this Agreement shall not be construed otherwise to create
a Valid Claim by contract.

 

		12.19	Licensee will promptly notify Licensor in writing if Licensee or any Sublicensees ceases to be a small entity (as defined by
the United States Patent and Trademark Office)

 

		12.20	This Agreement may be signed in one or more counterparts, each of which shall be deemed an original and all of which shall
be deemed one and the same document. Counterparts may be signed and delivered by facsimile or PDF file, each of which shall be
binding when received by the applicable party.

 

    	 	- 29 -	 

     

    

 

		12.21	Neither party shall be liable for any failure of or delay in the performance of this Agreement for the period that such failure
or delay is due to causes beyond its reasonable control, including but not limited to acts of god, war, strikes or labor disputes,
embargoes, action or inaction of a government agency or any other force majeure event.

 

		13.	Notices

 

		13.01	Any correspondence, document, notice or report required or permitted hereunder shall be given in writing, and shall be deemed
to have been properly given and effective upon delivery, by registered or certified mail, return receipt requested, or by facsimile
with proof of receipt and a confirmation copy sent by overnight courier, or by email with proof of receipt and a confirmation copy
sent by overnight courier, or by overnight courier to the following addresses or to such other address that a party may give by
written notice to all parties:

 

To Licensee: 

 

Cue Biopharma Inc.

c/o MDB Capital Group LLC

401 Wilshire Blvd, Suite 1020

Santa Monica, CA 90401

 

with copies to:

 

Scott E. Bartel, Esq.

Locke Lord LLP

500 Capitol Mall, Suite 1800

Sacramento, CA 95814

sbartel@lockelord.com

 

To Licensor: 

 

Albert Einstein College of Medicine,
Inc.

 

1300 Morris Park Avenue

Bronx, New York 10461

Attention: Office of Biotechnology

John.Harb@einstein.yu.edu

 

    	 	- 30 -	 

     

    

 

with copies to:

 

Kenneth P. George, Esq.

Amster, Rothstein & Ebenstein
LLP

90 Park Avenue

New York, NY 10016

kgeorge@arelaw.com

 

    	 	- 31 -	 

     

    

  

IN WITNESS WHEREOF, the parties have entered
into this Agreement effective as of the day and year first above written.

  

	 	 	ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
	WITNESS	 	 
	 	 	/s/ John L. Harb
	 	 	Name: John L. Harb
	 	 	Title Assistant Dean

 

	Date:	 	 	Date: 	July 31, 2017

 

	 	 	CUE BIOPHARMA INC.
	WITNESS	 	 
	 	 	/s/ Daniel R. Passeri
	 	 	Name Daniel R. Passeri
	 	 	Title President & CEO

 

	Date:	 	 	Date: 	July 31, 2017

 

	AGREED TO AND ACCEPTED BY:	 	 
	 	 	 
	/s/ Steven C. Almo	 	 

 

	Date: 	July 31, 2017	 	 

 

    	 	- 32 -	 

     

    

 

APPENDIX A - Agreement Patents

 

(1)         "Methods for
high throughput receptor-ligand identification," Application No. PCT/US13/73275 (Einstein Invention Disclosure No. D-972;
ARE Client Matter No. 96700/2061; Inventors: Steven C. Almo, Ronald D. Seidel, Brandan S. Hillerich, Sarah C. Garrett-Thomson and
James D. Love) (Assignee: Einstein) filed nationally in the United States, Australia, Brazil, Canada, China, EPO, Hong Kong, Israel,
India, Japan, South Korea and Singapore;

 

(2)         "Cellular
platform for rapid and comprehensive T-cell immunomonitoring," Application No. 61/929,651 (Einstein Invention Disclosure No.
D-1046; ARE Client Matter No. 96700/2095; Inventors: Steven C. Almo, Ronald D. Seidel, Brandan S. Hillerich and Rodolfo J. Chaparro)
(Assignee: Einstein);

 

(3)         "SYNTAC Fc
fusion constructs and uses thereof," Application No. 62/013,715 (Einstein Invention Disclosure No. D-1073; ARE Client Matter
No. 96700/2138; Inventors: Steven C. Alma, Ronald D. Seidel, Rodolfo J. Chaparro, Brandan S. Hillerich and Scott J. Garforth) (Assignee:
Einstein); and

 

(4)         "VARIANT PD-L1
POLYPEPTIDES, T-CELL MODULATORY MULTIMERIC POLYPEPTIDES, AND METHODS OF USE THEREOF" (Application No. 62/338,128); (Case No.
C-00001209; ARE Client Matter No. 96700/2347; Inventors: Steven C. Almo, Sarah C. Garrett-Thomson and Ronald D. Seidel (Assignee:
Einstein).

 

(5)         "Methods for
high throughput receptor-ligand identification," Application No. 61/735,791, (Einstein Invention Disclosure No. D-972; ARE
Client Matter No. 96700/1928; Inventors: Steven C. Almo, Ronald D. Seidel, Brandan S. Hillerich, Sarah C. Garrett-Thomson and James
D. Love) (Assignee: Einstein);

 

(6)         "Methods for
high throughput receptor-ligand identification," Application No. 61/833,588, (Einstein Invention Disclosure No. D-972; ARE
Client Matter No. 96700/1961; Inventors: Steven C. Almo, Ronald D. Seidel, Brandan S. Hillerich, Sarah C. Garrett-Thomson and James
D. Love) (Assignee: Einstein);

 

(7)         "Cellular
platform for rapid and comprehensive T-cell immunomonitoring," Application No. PCT/US15/012160 (Einstein Invention Disclosure
No. D-1046; ARE Client Matter No. 96700/2199; Inventors: Steven C. Almo, Ronald D. Seidel, Brandan S. Hillerich and Rodolfo J.
Chaparro) (Assignee: Einstein) filed nationally in the United States, Australia, Brazil, Canada, China, EPO, Israel, India, Japan,
South Korea and Singapore;

 

    	 	- 33 -	 

     

    

 

(8)         "SYNTAC Fc
fusion constructs and uses thereof," Application No. PCT/US15/035777 (Einstein Invention Disclosure No. D-1073; ARE Client
Matter No. 96700/2236; Inventors: Steven C. Almo, Ronald D. Seidel, Rodolfo J. Chaparro, Brandan S. Hillerich and Scott J. Garforth)
(Assignee: Einstein) filed nationally in the United States, Australia, Brazil, Canada, China, EPO, Taiwan, Israel, India, Japan,
South Korea and Singapore;

 

(9)         "VARIANT PD-LI
POLYPEPTIDES, T-CELL MODULATORY MULTIMERIC POLYPEPTIDES, AND METHODS OF USE THEREOF," Application No. PCT/US2017/33042; (Einstein
Invention Disclosure No. unknown; ARE Client Matter No. 96700/2508; Inventors: Steven C. Almo, Sarah C. Garrett-Thomson and Ronald
D. Seidel) (Assignee: Einstein).

 

    	 	- 34 -	 

     

    

 

APPENDIX B - March 5, 2015 Letter

 

(begins on next page)

 

 

 

 

 

 

 

 

 

 

 

    	 	A-3	 

     

    

 

	 
	 	 
	90 Park Avenue

New York NY 10016
	Main     	212 336 8000
	Fax	212 336 8001
	Web	www.arelaw.com

 

	March 5, 2015	Kenneth P. George

Direct 212 336 8090

E-mail kgeorge@arelaw.com

Via E-mail

 

Imagen Biopharma, Inc.

c/o MDB Capital Group LLC

401 Wilshire Blvd, Suite 1020

Santa Monica, CA 90401

Attention: Cameron Gray, President

 

	Yeshiva University
	2495 Amsterdam Avenue
	Suite BH 1001
	New York, New York 10033-3201
	Attention:  	Andrew Lauer 

	 	Vice President for Legal Affairs,
	 	Secretary and General Counsel
	 	 	 
	 	          Re:   	Joint Representation Letter
	 	 	[***]

 

Dear Cameron and Avi:

 

[***]Exhibit 10.21

 

CONFIDENTIAL
PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
FOR SUCH PORTIONS. ASTERISKS DENOTE OMISSIONS.

 

EXCLUSIVE PATENT LICENSE AND RESEARCH

COLLABORATION
AGREEMENT

 

by and between

 

Cue
Biopharma, Inc.

 

and

 

MERCK SHARP & DOHME CORP.

 

    	 	1	 

     

    

 

EXCLUSIVE PATENT LICENSE AND RESEARCH COLLABORATION
AGREEMENT

 

This Agreement
( “Agreement”) is effective as of November 14, 2017, (the “Effective
Date”) and is entered into by and between CUE BIOPHARMA, INC., a corporation organized and existing under the laws of
Delaware (“Company”) and MERCK SHARP & DOHME CORP., a corporation organized and existing under the laws
of New Jersey (“Merck”).

 

RECITALS:

 

WHEREAS, Company has developed Company
Know-How (as hereinafter defined) and has rights to Company Patent Rights (as hereinafter defined) related to antigen-specific
T cell-targeted biologics, including an exclusive license to certain intellectual property rights pursuant to an Amended and Restated
License Agreement dated July 31, 2017 between Company and Albert Einstein College of Medicine, Inc. (“Albert Einstein”),
a corporation organized and existing under the laws of the State of New York, having an office and place of business at 1300 Morris
Park Avenue, Bronx, New York 10461 as successor-in-interest to Albert Einstein College of Medicine of Yeshiva University, a Division
of Yeshiva University (the “Amended and Restated Einstein License Agreement”);

 

WHEREAS, such antigen-specific T cell-targeted
biologics have multiple potential uses, including but not limited to the treatment of Autoimmune Disease (as hereinafter defined),
cancer, and infectious diseases;

 

WHEREAS, Merck and Company desire to
enter into a research collaboration to research and develop certain antigen-specific T cell-targeted biologics and in particular
Cue Biologics, Compounds and Products of potential utility for treating Initial Indications in Autoimmune Disease (as those terms
are hereinafter defined) upon the terms and conditions set forth herein, with the goal of identifying and/or optimizing novel biologics
to be developed and commercialized by Merck;

 

WHEREAS, Merck desires to obtain a license
under the Company Patent Rights and Company Know-How upon the terms and conditions set forth herein, and Company desires to grant
such a license;

 

NOW, THEREFORE, in consideration of
the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which are hereby acknowledged,
Company and Merck hereby agree as follows:

 

Article
1  DEFINITIONS.

 

Unless specifically set forth to the contrary herein, the following
terms, whether used in the singular or plural, shall have the respective meanings set forth below.

 

		1.1	“AAALAC” shall mean the Association for Assessment
and Accreditation of Laboratory Animal Care International.

 

		1.2	“Act” shall mean, as applicable, the United States
Federal Food, Drug and Cosmetic Act, 21 U.S.C. §§ 301 et seq., and/or the Public Health Service Act, 42 U.S.C. §§
262 et seq., as amended from time to time.

 

    	 	2	 

     

    

 

		1.3	“Affiliate” shall mean: (i) any corporation or business
entity of which, now or hereafter, fifty percent (50%) or more of the securities or other ownership interests representing the
equity, the voting stock or general partnership interest are owned, controlled or held, directly or indirectly, by Merck or Company;
or (ii) any corporation or business entity which, now or hereafter, directly or indirectly, owns, controls or holds fifty percent
(50%) (or the maximum ownership interest permitted by law) or more of the securities or other ownership interests representing
the equity, the voting stock or, if applicable, the general partnership interest, of Merck or Company; or (iii) any corporation
or business entity of which, now or hereafter, fifty percent (50%) or more of the securities or other ownership interests representing
the equity, the voting stock or general partnership interest are owned, controlled or held, directly or indirectly, by a corporation
or business entity described in (i) or (ii).

 

		1.4	“Agreement” shall have the meaning given such term
in the preamble to this document.

 

		1.5	“Antigen” as used herein shall mean any protein or
Peptide that, when bound or presented by a Disease-Associated Allele, binds to T cells or evokes an immune response. 

 

		1.6	“Applicable Laws” means any and all applicable laws
of any jurisdiction which are applicable to any of the Parties or their respective Affiliates in carrying out activities hereunder
or to which any of the Parties or their respective Affiliates in carrying out the activities hereunder is subject, and shall include
all statutes, enactments, acts of legislature, laws, ordinances, rules, regulations, notifications, guidelines, policies, directions,
directives and orders of any statutory authority, tribunal, board, or court or any central or state government or local authority
or other governmental entity in such jurisdictions, including the Act, GLPs, GCPs and GMPs.

 

		1.7	“Autoimmune Disease” means a disease or inflammatory
disorder in which the body’s immune system produces antibodies and/or pro-inflammatory chemical agents that attack its own
tissues, leading to the deterioration and in some cases to the destruction of such tissue.

 

		1.8	“Calendar Quarter” shall
mean the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31.

 

		1.9	“Calendar Year” shall mean each successive period
of twelve (12) months commencing on January 1 and ending on December 31.

 

		1.10	“Change of Control” shall mean with respect to a
Party: (1) the sale of all or substantially all of such Party’s assets or business relating to this Agreement; (2) a merger,
reorganization or consolidation involving such Party in which the voting securities of such Party outstanding immediately prior
thereto cease to represent at least fifty percent (50%) of the combined voting power of the surviving entity immediately after
such merger, reorganization or consolidation; or (3) a person or entity, or group of persons or entities, acting in concert acquire
at least fifty percent (50%) of the voting equity securities or management control of such Party. 

 

		1.11	“Clinical Trial” shall mean a Phase I Clinical Trial,
Phase II Clinical Trial, Phase III Clinical Trial, and/or Post-Approval Clinical Trial. 

 

		1.12	“Combination Product” shall mean a Product that includes one or more active
pharmaceutical ingredients other than Compound in combination with Compound. All references to Product in this Agreement shall
be deemed to include Combination Product.

 

    	 	3	 

     

    

 

		1.13	“Commercially Reasonable Efforts” shall mean, with respect to the efforts to
be expended by a Party with respect to any objective, such reasonable and diligent, good faith efforts to accomplish such objective
as such Party would normally use to accomplish a similar objective under similar circumstances. It is understood and agreed that
with respect to the Research, Development and Commercialization of Product by either Party, such efforts shall be substantially
equivalent to those efforts and resources commonly used by such Party for biological products owned by it or to which it has rights,
which product is at a similar stage in its Development or product life and is of similar market potential taking into account efficacy,
safety, approved labeling, the competitiveness of alternative products in the marketplace, the patent and other proprietary position
of the product, the likelihood of regulatory approval given the Regulatory Authority involved, the profitability of the product
including the amounts payable to licensors of patent or other intellectual property rights, alternative products, other risks associated
with the Development or Commercialization of the product and other relevant factors. Commercially Reasonable Efforts shall be determined
on a market-by-market and Indication-by-Indication basis for a particular Product, and it is anticipated that the level of effort
will be different for different markets, and will change over time, reflecting among other things changes in the status of the
Product and the market(s) involved.

 

		1.14	“Commercialization” shall mean any and all activities
related to the import, export, transportation, storage, marketing, detailing, promotion, distribution, sale or other disposition
and/or other approved use of a Product in a country or region in the Territory, including: (a) strategic marketing, sales force
detailing, advertising, medical affairs, reimbursement and market access activities and market and product support; and (b) all
customer support, distribution matters, invoicing and sales activities. When used as a verb, “to Commercialize” and
“Commercializing” means to engage in Commercialization, and “Commercialized” has a corresponding meaning.
For clarity, Commercialization excludes any Research, Development or Manufacturing activities.

 

		1.15	“Company” shall have the meaning given such term
in the preamble to this Agreement.

 

		1.16	“Company Information and Inventions” shall mean all
protocols, formulas, data, Inventions, know-how and trade secrets, patentable or otherwise, resulting from the Research Program
developed or invented solely by employee(s) of Company and/or its Affiliates, and/or a Third Party acting on behalf of Company
and/or its Affiliates, and not employed by Merck and/or its Affiliates.

 

		1.17	“Company Know-How” shall mean all information and
materials, including but not limited to discoveries, improvements, processes, methods, protocols, formulas, data, inventions (including
without limitation Company Information and Inventions and Company’s rights in Joint Information and Inventions), know-how
and trade secrets, patentable or otherwise, which during the term of this Agreement: (i) are Controlled by Company or its Affiliates;
(ii) are not generally known; and (iii) are necessary or useful to Merck in the Field, or necessary or useful to Merck in connection
with the Research Program and the Research, Development, Manufacture, Commercialization or use of Compound or Product in the Territory;
excluding, however, any Merck Know-How. Company Know-How includes Einstein Know-How and Cue Know-How. 

 

		1.18	“Company Patent Rights” shall mean Patent Rights
that during the term of this Agreement are Controlled by Company or any of its Affiliates, including, but not limited to, those
listed on Schedule 1.1, which: (i) claim or cover a Cue Biologic, Compound and/or Product, or a method of use or process
of Manufacture thereof, including without limitation any improvements; or (ii) claim or cover Company Information and Inventions.
Company Patent Rights include Einstein Patent Rights and Cue Patent Rights. 

 

    	 	4	 

     

    

 

		1.19	“Competing Pharma” shall mean a company or group
of companies acting in concert (a) for which the collective worldwide sales of ethical pharmaceutical products in the preceding
Calendar Year were one billion United States dollars (US$1,000,000,000) or more, or (b) which has a research, development or commercialization
program for any preparation or product that may be used for the treatment of an Initial Indication, or any other preparation or
product that is reasonably considered to be competitive with any Cue Biologic, Compound or Product.

 

		1.20	“Competing Pharma Change of Control” shall mean a
Change of Control in which a company or group of companies acting in concert (a) for which the collective worldwide sales of ethical
pharmaceutical products in the Calendar Year that preceded the Change of Control were one billion United States dollars (US$1,000,000,000)
or more, or (b) which has a research, development or commercialization program for any preparation or product that may be used
for the treatment of an Initial Indication, or any other preparation or product that is reasonably considered to be competitive
with any Cue Biologic, Compound or Product, is the acquirer (by asset purchase, merger, consolidation, reorganization or otherwise)
as part of such Change of Control.

 

		1.21	“Compound” shall mean a Product Candidate; or a derivative thereof [***].

 

		1.22	“Control”,
“Controls” or “Controlled by” shall
mean with respect to any item of or right under Company Patent Rights, Company Know-How, Merck Patent Rights, Merck Know-How, or
Joint Patent Rights, or other intellectual property assets or rights, as applicable, the possession of (whether by ownership or
license, other than pursuant to this Agreement) or the ability of a Party to grant access to, or a license or sublicense of, such
items or right as provided for herein without violating the terms of any agreement or other arrangement with any Third Party existing
at the time or in effect during the time such Party would be required hereunder to grant the other Party such access or license
or sublicense.

 

		1.23	“Cue Biologic” shall mean [***].

 

		1.24	“Cue Biologics Patent Rights” shall be as defined
in Section 7.1.1. 

 

		1.25	“Cue Biologics-Specific Information and Inventions” shall
be as defined in Section 7.1.1. 

 

		1.26	“Cue Know-How” shall man all Company Know-How other
than Einstein Know-How.

 

		1.27	“Cue Patent Rights” shall mean all Company Patent
Rights other than Einstein Patent Rights.

 

		1.28	“Cue Platform”
shall mean Company’s proprietary Antigen-specific T cell-targeted biologic platform that produces biologics designed and
engineered to selectively modulate function of T cell subsets. 

 

		1.29	“Cue Platform Biologic” shall mean [***].

 

		1.30	“Development” means any and all clinical drug development
activities, Clinical Trials, statistical analysis and report writing, the preparation and submission of regulatory filings, regulatory
affairs with respect to the foregoing and all other activities necessary or reasonably useful or otherwise requested or required
by a Regulatory Authority as a condition or in support of obtaining or maintaining a regulatory approval for a Cue Biologic, Compound
or Product, and “Develop”, “Developed” and “Developing” will have corresponding meanings. For
clarity, Development excludes any Research, Commercialization or Manufacturing activities. 

 

    	 	5	 

     

    

 

		1.31	“Disease-Associated Allele” shall mean any allele
from any species which is associated with [***]. 

 

		1.32	“Einstein Know-How” shall mean all know-how licensed
to Company under the Amended and Restated Einstein License Agreement.

 

		1.33	“Einstein Patent Rights” shall mean all patent rights
licensed to Company under the Amended and Restated Einstein License Agreement.

 

		1.34	“Exclusions Lists” shall be as defined in Section
1.90 Violation. 

 

		1.35	“Field” shall mean [***].

 

		1.36	“First
                                         Collaborative Cue Biologic” shall mean the
                                         first Cue Biologic synthesized under the Research Program [***].

 

		1.37	“First Commercial Sale” shall mean, with respect
to any Product, the first sale for end use or consumption of such Product in a country, excluding, however, any sale or other distribution
for use in a Clinical Trial.

 

		1.38	“Good Clinical Practices” or “GCPs”
shall mean the applicable then-current Good Clinical Practices as such term or its equivalent
is defined from time to time by the United States Food and Drug Administration or other relevant Regulatory Authority having jurisdiction
over the Development, Manufacture or Commercialization of Product in the Territory pursuant to its regulations, guidelines or otherwise,
as applicable.

 

		1.39	“Good Laboratory Practices” or “GLPs”
shall mean the applicable then-current standards for laboratory activities for pharmaceuticals
or biologicals, as set forth in the Act and any regulations or guidance documents promulgated thereunder, as amended from time
to time, together with any similar standards of good laboratory practice as are required by any Regulatory Authority in the Territory.

 

		1.40	“Good Manufacturing Practices” or “GMPs”
shall mean the applicable then-current Good Manufacturing Practices as such term or its equivalent
is defined from time to time by the United States Food and Drug Administration or other relevant Regulatory Authority having jurisdiction
over the Development, Manufacture or Commercialization of Product in the Territory pursuant to its regulations, guidelines or otherwise,
as applicable.

 

		1.41	“Human Leukocyte Antigen” or “HLA”
shall mean a protein or protein complex involved in the presentation of Peptide antigens to T
cells. 

 

		1.42	[****]

 

		1.43	“IND” shall mean an investigational new drug application,
clinical study application, clinical trial exemption, or similar application or submission for approval to conduct human clinical
investigations filed with or submitted to a Regulatory Authority in conformance with the requirements of such Regulatory Authority.

 

    	 	6	 

     

    

 

		1.44	“IND Enabling Studies” shall mean the genotoxicity,
acute toxicology, safety, pharmacology, and/or sub-chronic toxicology studies in species using applicable GLPs that in Merck’s
sole discretion satisfy applicable regulatory requirements and meet the standard necessary for submission as part of an IND filing
with a Regulatory Authority. 

 

		1.45	“Indication” shall mean a separate and distinct disease
or medical condition in humans which a Product that is in Clinical Trials is intended to treat, prevent and/or diagnose and/or
for which a Product has received Marketing Authorization.

 

		1.46	“Indication Specific Peptide” shall mean a Peptide
Researched or Developed pursuant to the Research Program which is [***]. 

 

		1.47	“Initial Indication” shall mean [***]
and “Initial Indications” shall mean [***],
collectively. 

 

		1.48	“Information” shall mean any and all information
and data, including without limitation all Merck Know-How, all Company Know-How, and all other scientific, pre-clinical, clinical,
regulatory, manufacturing, marketing, financial and commercial information or data, whether communicated in writing or orally or
by any other method, which is provided by one Party to the other Party in connection with this Agreement.

 

		1.49	“Invention”
shall mean any process, method, composition of matter, article of manufacture, discovery or finding
that is conceived and/or reduced to practice as a result of the Research Program. 

 

		1.50	“Joint Information and Inventions” shall mean all
protocols, formulas, data, Inventions, know-how and trade secrets, patentable or otherwise, resulting from the Research Program
and developed or invented jointly by employee(s) of Merck and/or its Affiliates, and/or a Third Party acting on behalf of Merck
and/or its Affiliates, on the one hand, and by employee(s) of Company and/or its Affiliates, and/or a Third Party acting on behalf
of Company and/or its Affiliates, on the other hand.

 

		1.51	“Joint Patent Rights” shall mean Patent Rights that
claim or cover Joint Information and Inventions. 

 

		1.52	“Joint Steering Committee”
shall mean the joint steering committee established to facilitate the Research Program as more
fully described in Section 2.4.

 

		1.53	“Maintained Initial Indication”
shall mean an Initial Indication in which Merck has not discontinued Research, Development and Commercialization efforts with respect
to any Compound or Product pursuant to Section 2.11.5. 

 

		1.54	“Major Market” shall mean [***].

 

		1.55	“Manufacturing” means the production, manufacture,
synthesis, processing, filling, formulating, finishing, packaging, labeling, shipping and holding of Cue Biologic, Compound or
Product or any intermediate thereof, including sequencing, process development, process qualification and validation, scale-up,
commercial manufacture and analytic development, product characterization, stability testing, quality assurance and quality control.
“Manufacturing” refers to both pre-clinical and clinical Manufacturing for Research and Development, and Manufacturing
for Commercialization. “Manufacture” and “Manufactured” will have corresponding meanings. For clarity,
“Manufacturing” excludes Research, Development or Commercialization activities. 

 

    	 	7	 

     

    

 

		1.56	“Marketing Authorization” shall mean all approvals
from the relevant Regulatory Authority necessary to market and sell a Product in the applicable country (including without limitation,
in countries outside of the United States, all applicable pricing and governmental reimbursement approvals only if required to
market and sell Product in a country).

 

		1.57	“Merck” shall have the meaning given such term in
the preamble to this Agreement.

 

		1.58	“Merck Information and Inventions” shall mean all
protocols, formulas, data, Inventions, know-how and trade secrets, patentable or otherwise, resulting from the Research Program
developed or invented solely by employee(s) of Merck and/or its Affiliates, and/or a Third Party acting on behalf of Merck and/or
its Affiliates, and not employed by Company and/or its Affiliates.

 

		1.59	“Merck Know-How” shall mean all information and materials,
including but not limited to discoveries, improvements, processes, methods, protocols, formulas, data, inventions (including without
limitation Merck Information and Inventions and Merck’s rights in Joint Information and Inventions), know-how and trade secrets,
patentable or otherwise, which during the term of this Agreement: (i) are Controlled by Merck; (ii) are not generally known; and
(iii) are in Merck’s opinion necessary to Company in the performance of its obligations under the Research Program.

 

		1.60	“Merck Patent Rights” shall mean Patent Rights that
during the term of this Agreement are Controlled by Merck or any of its Affiliates, or to which Merck or any of its Affiliates,
through license or otherwise, acquires rights, which: (i) claim or cover Compound and/or Product; or (ii) claim or cover Merck
Information and Inventions. 

 

		1.61	“NDA” shall mean a new drug application, biologics
license application, Marketing Authorization application, filing pursuant to Section 510(k) of the Act, or similar application
or submission for Marketing Authorization of a Product filed with a Regulatory Authority to obtain marketing approval for a biological,
pharmaceutical or diagnostic product in that country or in that group of countries.

 

		1.62	“Net Sales” shall mean the gross invoice price (not
including value added taxes, sales taxes, or similar taxes) of Product sold by Merck or its Related Parties to the first Third
Party after deducting, if not previously deducted, from the amount invoiced or received:

 

		1.62.1	trade and quantity discounts, other than early payment cash discounts;

 

		1.62.2	returns, rebates, chargebacks and other allowances;

 

		1.62.3	retroactive price reductions that are actually allowed or granted;

 

		1.62.4	deductions for Health Care Reform fees and similar deductions to gross invoice price of Product
imposed by Regulatory Authorities or other governmental entities;

 

    	 	8	 

     

    

 

		1.62.5	a fixed amount equal to [***] of the amount invoiced to cover bad debt, early payment cash discounts,
transportation and insurance and custom duties; and

 

		1.62.6	the standard inventory cost of devices or delivery systems used for dispensing or administering
Product.

 

[***]

 

With respect to sales of Combination
Products, Net Sales shall be calculated on the basis of the gross invoice price of Product(s) containing the same strength of Compound
sold without other active ingredients. In the event that Product is sold only as a Combination Product, Net Sales shall be calculated
on the basis of the gross invoice price of the Combination Product multiplied by a fraction, the numerator of which shall be the
inventory cost of Compound in the Product and the denominator of which shall be the inventory cost of all of the active ingredients
in the Combination Product. Inventory cost shall be determined in accordance with Merck's regular accounting methods, consistently
applied. The deductions set forth in Section 1.62.1 through Section 1.62.6 will be applied in calculating Net Sales
for a Combination Product. In the event that Product is sold only as a Combination Product and either Party reasonably believes
that the calculation set forth in this Paragraph does not fairly reflect the value of Compound relative to the other active ingredients
in the Combination Product, the Parties shall reasonably negotiate, in good faith, other means of calculating Net Sales with respect
to Combination Products.

 

		1.63	“Party” shall
mean Merck or Company, individually, and “Parties” shall mean Merck and Company, collectively.

 

		1.64	“Patent Rights” shall mean any and all patents and
patent applications in the Territory (which for the purpose of this Agreement shall be deemed to include certificates of invention
and applications for certificates of invention), including divisionals, continuations, continuations-in-part, reissues, renewals,
substitutions, registrations, re-examinations, revalidations, extensions, supplementary protection certificates, pediatric exclusivity
periods and the like of any such patents and patent applications, and foreign equivalents of the foregoing.

 

		1.65	“Peptide” shall mean a series of two or more amino
acids connected by peptide bonds. 

 

		1.66	“Person” means any individual, partnership, joint
venture, limited liability company, corporation, firm, trust, association, unincorporated organization, governmental authority
or agency, or any other entity not specifically listed herein.

 

		1.67	“Phase I Clinical Trial” shall mean a human clinical
trial in any country that would satisfy the requirements of 21 CFR 312.21(a).

 

		1.68	“Phase II Clinical Trial” shall mean a human clinical
trial in any country that would satisfy the requirements of 21 CFR 312.21(b).

 

		1.69	“Phase III Clinical Trial” shall mean a human clinical
trial in any country that would satisfy the requirements of 21 CFR 312.21(c).

 

		1.70	“Platform Information and Inventions” shall be as
defined in Section 7.1.2. 

 

		1.71	“Platform Patent Rights” shall be as defined in Section
7.1.2. 

 

    	 	9	 

     

    

 

		1.72	“Post-Approval Clinical Trial” shall mean any clinical
trial conducted in an Indication after the Regulatory Approval of such Indication. 

 

		1.73	“Product(s)” shall mean any pharmaceutical or biological
preparation in final form containing a Compound: (i) for sale by prescription, over-the-counter or any other method; or (ii) for
administration to human patients in a Clinical Trial, for any and all uses in the Field, including without limitation any Combination
Product.

 

		1.74	“Product Candidate” shall mean a Cue Biologic which:
(i) meets or exceed Proof of Concept, as determined by Merck in accordance with its usual procedures for the development of new
biological entities; and (ii) is designated in writing pursuant to Section 2.2.4 as a Product Candidate by Merck to Company.

 

		1.75	“Proof of Concept” shall mean the demonstration of
all or substantially all of the properties outlined in the Product Candidate Profile as defined in Schedule 2.1 Research
Program, as determined by Merck in its sole discretion.

 

		1.76	“Proof of Mechanism” shall mean the demonstration
of biologically significant effect of a Cue Biologic [***], as determined by the Joint
Steering Committee pursuant to Section 2.2.2.

 

		1.77	“Proposed Product Candidate”
shall be a Cue Biologic which has achieved Proof of Mechanism as determined by the Joint Steering Committee, as reflected in meeting
minutes of the Joint Steering Committee.

 

		1.78	“Qualifying Phase II Clinical Trial” shall mean a
human clinical trial, in any country, the principal purpose of which is a confirmation of efficacy and safety, consistent with
that observed in previous Clinical Trial(s) of the relevant Product, in the target population, at the intended clinical dose or
doses or range of doses, on a sufficient number of subjects and for a sufficient period of time to determine the optimal manner
of use of the Product (dose and dose regimen) prior to the Initiation of a Phase III Clinical Trial of such Product. For clarity,
the Parties’ expectation is that a Qualifying Phase II Clinical Trial will be a phase IIb Clinical Trial which is intended
to confirm the efficacy demonstrated in a prior phase IIa Clinical Trial or phase Ib Clinical Trial. 

 

		1.79	“Regulatory Authority” shall mean any applicable
government regulatory authority involved in granting approvals for the manufacturing, marketing, reimbursement and/or pricing of
a Product in the Territory, including, in the United States, the United States Food and Drug Administration and any successor governmental
authority having substantially the same function.

 

		1.80	“Regulatory T cells” or “T-regs” also
known as suppressor T cells, are a subpopulation of T cells which modulate the immune system, maintain tolerance to self-antigens,
and prevent autoimmune disease.

 

		1.81	“Related Party” shall mean each of Merck, its Affiliates,
and their respective sublicensees (which term does not include distributors), as applicable. 

 

		1.82	“Research” means activities related to the design,
discovery, identification, synthesis, research, pre-clinical development, preclinical toxicology studies, profiling, characterization,
improvement or optimization of a Cue Biologic, Compound or Product. For clarity, “Research” excludes Development, Commercialization
or Manufacturing activities.

 

    	 	10	 

     

    

 

		1.83	“Research Program” shall mean the Research activities
undertaken by the Parties as set forth in Article 2 and Schedule 2.1, as may be revised from time to time pursuant
to Section 2.1, Section 2.2, or Section 2.10.

 

		1.84	“Research Program Term” shall mean the duration of
the Research Program as it may be extended or terminated as described more fully in Section 2.10 and Article 8.

 

		1.85	“Royalty Period” shall be as defined in Section
5.4.1(c).

 

		1.86	“Term” is defined in Section 8.1.

 

		1.87	“Territory” shall mean all of the countries in the
world, and their territories and possessions.

 

		1.88	“Third Party” shall mean an entity other than Merck
and its Related Parties, and Company and its Affiliates. 

 

		1.89	“Valid Patent Claim” shall mean a claim of an issued,
unexpired and in-force patent included within the Company Patent Rights or Joint Patent Rights that claims a Compound as a composition
of matter, which claim has not been revoked or held unenforceable or invalid by a decision of a court or other governmental agency
of competent jurisdiction (which decision is not appealable or has not been appealed within the time allowed for appeal), and which
claim has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination, supplemental
examination or disclaimer or otherwise.

 

		1.90	“Violation”
                                         shall mean that either Company, or any of its officers
                                         or directors has been: (a) convicted of any of the felonies identified among the exclusion
                                         authorities listed on the U.S. Department of Health and Human Services, Office of Inspector
                                         General (OIG) website, including 42 U.S.C. 1320a-7(a) (https://oig.hhs.gov/exclusions/index.asp);
                                         and/or (b) identified in the OIG List of Excluded Individuals/Entities (LEIE) database
                                         (https://oig.hhs.gov/exclusions/exclusions_list.asp) or the U.S. General Services
                                         Administration's list of Parties Excluded from Federal Programs (https://www.sam.gov/portal/public/SAM/)
                                         (each of (a) and (b), singly and collectively, the “Exclusions Lists”).

 

    	 	11	 

     

    

 

Article
2  RESEARCH PROGRAM, GOVERNANCE, exclusive efforts

 

		2.1	General. Company and Merck shall engage in the Research Program
upon the terms and conditions set forth in this Agreement. The activities to be undertaken in the course of the Research Program
are set forth in Schedule 2.1 as may be revised from time to time upon mutual written agreement by authorized representative(s)
of the Parties.

 

		2.2	Conduct of Research. The Research Program is directed to: (i)
the Research by Company of Cue Biologics up to Proof of Mechanism for each of the Initial Indications; and, subject to Section
2.2.2; (ii) the further Research and/or Development by Merck of Proposed Product Candidates. Subject to Section 2.2.4,
Merck may, in its sole discretion, elect [****] Product Candidates for use by Merck and its Related Parties in efforts
to Research, Develop, Manufacture and Commercialize Compounds and Products.

 

		2.2.1	Until the expiration of the Research Program Term, Company and Merck each shall proceed diligently
with the work set out in the Research Program by using their respective reasonable good faith efforts to allocate sufficient time,
effort, equipment and facilities to the Research Program and to use personnel with sufficient skills and experience as are required
to accomplish the Research Program in accordance with the terms of this Agreement and Schedule 2.1 as may be revised from
time to time pursuant to Section 2.1.

 

		2.2.2	Upon the generation of data supporting achievement of Proof of Mechanism for each Cue Biologic,
Company shall present such information along with the identity of the Cue Biologic to the Joint Steering Committee. Following a
determination by the Joint Steering Committee that such Cue Biologic has achieved Proof of Mechanism as reflected in the meeting
minutes of the Joint Steering Committee, such Cue Biologic shall constitute a Proposed Product Candidate. Merck shall thereafter
perform the Research and/or Development activities assigned under the Research Program for the Proposed Product Candidate. Company
shall have responsibility for supply of such Proposed Product Candidate.

 

		2.2.3	Upon achievement of Proof of Concept for one or more Proposed Product Candidates, Merck shall provide
written notice to Company that such one or more Proposed Product Candidates have achieved Proof of Concept.

 

		2.2.4	Following written notice to Company of the achievement of Proof of Concept for a Proposed Product
Candidate, Merck shall conduct an internal review to determine in its sole discretion whether it wishes to elect the Proposed Product
Candidate as a Product Candidate. Merck shall then request through the Joint Steering Committee a meeting with Company to discuss
and mutually agree upon a technology transfer strategy to provide for the continued supply and Manufacturing of Product Candidates
for IND Enabling Studies. Following Merck’s request for a meeting pursuant to this Section 2.2.4 and mutual agreement
on the technology transfer strategy, Merck may elect in its sole discretion to designate a Proposed Product Candidate as a Product
Candidate and provide written notice to Company informing them of such election. Parties shall thereafter work to execute on the
mutually-agreed upon technology transfer strategy.

 

Merck shall be entitled
to utilize the services of its Affiliates and Third Parties to perform its Research Program activities, provided that all such
Affiliates and Third Parties are bound or agree to be bound by confidentiality and non-use obligations no less stringent than that
contained in this Agreement. Company shall be entitled to utilize the service of Third Parties to perform its Research Program
activities only upon Merck’s prior written consent or as specifically set forth in Schedule 2.1. Notwithstanding the
foregoing, each Party shall remain at all times fully liable for its respective responsibilities under the Research Program.

 

    	 	12	 

     

    

 

		2.3	Use of Research Funding. Company shall apply any Research funding
it receives from Merck under this Agreement solely to carry out its Research Program activities in accordance with Schedule
2.1, as may be revised from time to time pursuant to Section 2.1, and the terms and conditions of this Agreement. Apart
from the foregoing, each Party shall be responsible for its own cost and expense in carrying out its activities under the Research
Program.

 

		2.4	Joint Steering Committee. The Parties hereby establish a committee
to facilitate the Research Program as follows:

 

		2.4.1	Composition of the Joint Steering Committee. The Research Program shall be conducted under
the direction of a joint steering committee (the “Joint Steering
Committee”) comprised of two (2) Merck representatives (who shall be employees of Merck or its Affiliate, as applicable)
and two (2) Company representatives (who shall be employees of Company or its Affiliate, as applicable). Each Party may change
its representatives on the Joint Steering Committee from time to time in its sole discretion, effective upon notice to the other
Party of such change. These representatives shall have appropriate technical credentials, experience and knowledge, and ongoing
familiarity with the Research Program. Additional representative(s) or consultant(s) may from time to time, by mutual consent of
the Parties, be invited to attend Joint Steering Committee meetings, subject to such representative’s or consultant’s
written agreement to comply with the requirements of Section 4.1. The Joint Steering Committee shall be chaired by a representative
of Merck. The role of the chairperson shall be to preside in person or telephonically at meetings of the Joint Steering Committee,
to prepare and circulate agendas and to ensure the preparation of minutes. The chairperson of the Joint Steering Committee will
be responsible for preparing reasonably detailed written minutes of all Joint Steering Committee meetings that reflect, without
limitation, material decisions made at such meetings. The chairperson shall send draft meeting minutes to each member of the Joint
Steering Committee for review and approval reasonably promptly after each meeting. Such minutes will be deemed approved unless
one or more of the members of the Joint Steering Committee objects to the accuracy of such minutes within ten (10) business days
of receipt. Decisions of the Joint Steering Committee shall be made unanimously by the representatives. In the event that the Joint
Steering Committee cannot or does not, after reasonable good faith efforts, reach agreement on an issue, the resolution and/or
course of conduct shall be determined by Merck, in its sole discretion.

 

    	 	13	 

     

    

 

		2.4.2	Scope of Joint Steering Committee Oversight. The Joint Steering Committee shall be responsible
for overseeing the Research Program, including to: (i) review and amend the Research Program activities set forth in Schedule
2.1 as may be revised from time to time pursuant to Section 2.1; (ii) review and coordinate the Parties’ activities
under the Research Program; (iii) confer regarding the status of the Research Program and the progress under the Research Program
and to make determinations and decisions in connection with the activities under the Research Program (including issues of priority);
(iv) review relevant data under the Research Program; (v) consider and advise on any technical issues that arise under the Research
Program; (vi) review and advise on any budgetary and economic matters relating to the Research Program which may be referred to
the Joint Steering Committee; and (vii) to determine such other matters as allocated to the Joint Steering Committee hereunder.
The Joint Steering Committee shall not have the authority to: (w) modify or amend the terms and conditions of this Agreement; (x)
waive either Party’s compliance with the terms and conditions of this Agreement; (y) determine any issue in a manner that
would conflict with the express terms and conditions of this Agreement; or (z) amend the Research Program activities in a manner
that would increase the financial or other resource obligations imposed on the Company beyond the scope of those required under
the then current planned activities, and if such amendment would increase such financial or other resource obligations, then such
amendment must be mutually agreed to by the Parties in writing; provided that, for the avoidance of doubt if the work proposed
in the amendment to the Research Program activities could be performed with the financial or other resource obligations then currently
being funded by Merck and such work would not impose additional financial obligations on Company beyond the then current Research
Program activities, Company shall perform such work at no additional charge and the Research Program activities shall automatically
be deemed to be amended to include such work as proposed by the Joint Steering Committee.

 

		2.4.3	Meetings. During the Research Program Term, the Joint Steering Committee shall meet in accordance
with a schedule established by mutual written agreement of the Parties, but
no less frequently than once per Calendar Quarter, with the location for such meetings alternating between Company
and Merck facilities (or such other location may be determined by the Joint Steering Committee). Alternatively, the Joint Steering
Committee may meet by means of teleconference, videoconference or other similar communications equipment. Each Party shall bear
its own expenses related to the attendance of such meetings by its representatives.

 

		2.4.4	Disbandment of Joint Steering Committee. Upon completion (or earlier termination) of the
Research Program, the Joint Steering Committee shall be disbanded and shall have no further authority with respect to the activities
hereunder.

 

		2.5	Alliance Managers.

 

		2.5.1	Appointment. Each Party shall have the right to appoint an employee who shall oversee
interactions between the Parties for all matters related to this Agreement (each an “Alliance Manager”). Such
persons shall endeavor to ensure clear and responsive communication between the Parties and the effective exchange of information,
and may serve as a single point of contact for any matters arising under this Agreement. The Alliance Managers shall have the right
to attend all Joint Steering Committee meetings as non-voting participants and may bring to the attention of the Joint Steering
Committee any matters or issues either of them reasonably believes should be discussed, and shall have such other responsibilities
as the Parties may mutually agree in writing. Each Party may designate different Alliance Managers by notice in writing to the
other Party.

 

		2.5.2	Responsibilities of the Alliance Managers. The Alliance Managers, if appointed, shall
have the responsibility of creating and maintaining a constructive work environment between the Parties. Without limiting the generality
of the foregoing, each Alliance Manager shall:

 

		(a)	identify and bring disputes and issues that may result in disputes (including without limitation
any asserted occurrence of a material breach by a Party) to the attention of the Joint Steering Committee in a timely manner, and
function as the point of first referral in all matters of conflict resolution;

 

    	 	14	 

     

    

 

		(b)	provide a single point of communication for seeking consensus both internally within the Parties’
respective organizations and between the Parties;

 

		(c)	plan and coordinate cooperative efforts, internal communications and external communications between
the Parties with respect to this Agreement; and

 

		(d)	take responsibility for ensuring that meetings and the production of meeting agendas and minutes
occur as set forth in this Agreement, and that relevant action items resulting from such meetings are appropriately carried out
or otherwise addressed.

 

		2.6	Patent Committee. The Parties hereby establish a committee to
facilitate the filing, prosecution and maintenance of Patent Rights as follows:

 

		2.6.1	Establishment. Within sixty (60) days after the Effective Date, the Parties shall establish
a patent committee (the “Patent Committee”) to discuss, oversee and coordinate the filing, prosecution, maintenance
and enforcement of Merck Patent Rights, Company Patent Rights and Joint Patent Rights; and the filing of Patent Rights on Information
and Inventions (with the exception of Other Information and Inventions which are not Joint Information and Inventions); and defense
against claims of infringement of Third Party patents related to the intellectual property licensed or practiced under this Agreement.
The Patent Committee will provide recommendations to the Parties regarding the filing, prosecution, maintenance and enforcement
of such Patent Rights and related intellectual property matters.

 

		2.6.2	Membership; Meetings. The Patent Committee shall be composed of one (1) employee from each
of Merck and Company knowledgeable in U.S. patent law and the technology areas that are the subject of this Agreement. The Patent
Committee shall meet, in person, by teleconference, or by video-teleconference, at least one (1) time per Calendar Quarter, or
more or less often as the Parties shall determine. In-person meetings shall alternate between Company and Merck locations within
the United States whenever possible unless otherwise agreed by the Parties. The first such meeting shall be within ninety (90)
days after the Effective Date. Any member of the Patent Committee may designate a substitute, who shall be an employee of the applicable
Party, to attend with prior written notice to the other Party. Ad hoc guests who are subject to written confidentiality obligations
at least as stringent as the provisions in Article 4 may be invited to Patent Committee meetings. Each Party may replace
its Patent Committee members with other of its employees with the qualifications set forth in this Section 2.6.2, at any
time, upon written notice to the other Party.

 

		2.6.3	Recommendations; Limitations on Patent Committee.  Recommendations of the Patent Committee
shall be made by consensus, with each Party having collectively one (1) vote in all decisions. The Patent Committee shall have
only such powers as are specifically delegated to it in this Agreement and such powers shall be subject to the terms and conditions
set forth herein. Without limiting the generality of the foregoing, the Patent Committee shall have no power to amend this Agreement,
the Research Program or any written Research plan. Recommendations where the Patent Committee is unable to reach a consensus are
determined as follows:

 

    	 	15	 

     

    

 

		(a)	Merck shall have final decision-making authority with respect to any dispute relating specifically
to Cue Biologics-Specific Information and Inventions, Cue Biologics Patent Rights, and Merck Other Information and Inventions;

 

		(b)	Company shall have final decision-making authority with respect to any dispute relating specifically
to Platform Information and Inventions, Platform Patent Rights, and Company Other Information and Inventions; and

 

		(c)	The Patent Committee shall seek to resolve disputes concerning recommendations on Joint Other Information
and Inventions. If the Patent Committee is unable to reach a consensus recommendation on a matter that relates to the Joint Other
Information and Inventions within thirty (30) days after it has met and attempted to reach such recommendation, then either Party
may refer such matter for resolution by nominated executives of each Party.

 

The Patent Committee
shall provide status updates to the Joint Steering Committee once per Calendar Quarter as long as the Joint Steering Committee
is in existence and, thereafter, to the Parties.

 

Company shall update
Schedule 1.1 and provide such updated schedule to the Patent Committee on a monthly basis.

 

		2.6.4	Duration of Patent Committee. The Patent Committee shall endure for the Term and, by mutual
agreement, beyond the Term.

 

		2.7	Exchange of Information. Following execution of this Agreement,
and during the term of the Research Program, Company shall on a quarterly basis and at least ten (10) days before each Joint Steering
Committee meeting disclose to Merck in English and in writing or in an electronic format, any: [***].
Notwithstanding the foregoing, the Information exchanged pursuant to this Section 2.7 or the subject of a Company representation
pursuant to Article 6 does not in any way limit the definition of Company Know-How as employed throughout the Agreement.

 

		2.8	Records and Reports.

 

		2.8.1	Records. Company shall maintain records, in sufficient detail and in good scientific manner
appropriate for patent and regulatory purposes, which shall fully and properly reflect all work done and results achieved in the
performance of the Research Program by Company.

 

		2.8.2	Copies and Inspection of Records. Merck shall have the right, during normal business hours
and upon reasonable notice, to inspect and copy all such records of Company referred to in Section 2.8.1. Merck shall maintain
such records and the information disclosed therein in confidence in accordance with Section 4.1. Merck shall have the right
to arrange for its employee(s) and/or consultant(s) involved in the activities contemplated hereunder to visit the offices and
laboratories of Company and any of its Third Party contractors as permitted under Section 2.2 during normal business hours
and upon reasonable notice, and to discuss the Research Program work and its results in detail with the technical personnel and
consultant(s) of Company. Upon request, Company shall provide copies of the records described in Section 2.8.1.

 

    	 	16	 

     

    

 

		2.8.3	Quarterly Reports. Within thirty (30) calendar days following the end of each Calendar Quarter
during the term of this Agreement, Company shall provide to Merck a written progress report in English which shall describe the
work performed to date on the Research Program, evaluate the work performed in relation to the goals of the Research Program and
provide such other information as may be required by the Research Program or reasonably requested by Merck relating to the progress
of the goals or performance of the Research Program. For clarity, all such reports shall be considered the confidential Information
of Merck.

 

		2.9	Research Information and Inventions. The entire right, title
and interest in:

 

		2.9.1	Company Information and Inventions shall be owned solely by Company;

 

		2.9.2	Merck Information and Inventions shall be owned solely by Merck; and

 

		2.9.3	Joint Information and Inventions shall be owned jointly by Company and Merck.

 

Company shall promptly disclose to
Merck in writing the development, making, conception or reduction to practice of Company Information and Inventions and Joint Information
and Inventions. For the purposes of determining ownership under this Section 2.9, inventorship shall be determined in accordance
with United States patent laws (regardless of where the applicable activities occurred). Subject to the licenses granted to the
other party under this Agreement and the other terms and conditions of this Agreement, each Party shall have the non-exclusive
right to exploit its interest in Joint Information and Inventions and Joint Patent Rights, and to grant licenses under its interest
in Joint Information and Inventions and Joint Patent Rights, as it deems appropriate, without the consent of, and without accounting
to, the other Party; provided, however, that for clarity, the foregoing joint ownership rights shall not be construed
as granting, conveying or creating any license or other rights to the other Party’s intellectual property, unless otherwise
expressly set forth in this Agreement; and further provided that, in the event that any Joint Patent Rights claim or cover
a Compound or the Manufacturing process therefor, Company shall not grant any license under its interest in such Joint Patent Rights
to any Third Party without Merck’s prior written consent.

 

		2.10	Research Program Term. The term of the Research Program shall
commence on the Effective Date and continue until the later of: (i) election of [****] Product Candidates; or (ii) [****] from the Effective Date, except as provided below in Section 2.10.1 or as otherwise stated herein.

 

		2.10.1	Extensions. The term of the Research Program may be extended by Merck at its sole discretion
for a total of [****] additional years on a year-by-year basis. To exercise each of these extensions, Merck shall provide
written notice of such request at least ninety (90) days prior to the expiration of the then current Research Program term. For
each extension exercised pursuant to this Section 2.10.1, the Parties shall work together to mutually agree on a revised
Research Program and Schedule 2.1. Such revised Research Program shall be encompassed within the definition of Research
Program for purposes of this Agreement.

 

		2.11	Exclusive Efforts.

 

		2.11.1	Cue
                                         Biologics, Compounds, Indication Specific Peptides. During the Research Program Term,
                                         Company shall keep Merck informed of any Indication Specific Peptide or of any Cue Biologic
                                         or Compound that is Researched or Developed for use in an Initial Indication. During
                                         the Research Program Term, Company shall, and shall cause its Affiliates and Third Parties
                                         working on Company’s behalf to, work exclusively (even as to Company itself) with Merck
                                         in efforts to research, develop, make, have made, use, sell, offer for sale, import or
                                         otherwise exploit, or license any rights in intellectual property to any Cue Biologic,
                                         Compound, or Indication Specific Peptide for an Initial Indication, other than for performing
                                         Company’s obligations under the Research Program in accordance with this Agreement.

 

    	 	17	 

     

    

 

		2.11.2	Cue
                                         Platform Biologics. Company, its Affiliates and Third Parties working on Company’s
                                         behalf, may independently engage in research, discovery, development and commercialization
                                         of Cue Platform Biologics: (i) for any purpose outside of Autoimmune Disease from the
                                         Effective Date until the earlier of a) achievement of Proof of Mechanism for the first
                                         Cue Biologic, or b) eighteen (18) months after Company’s written notice to the
                                         Joint Steering Committee of the First Collaborative Cue Biologic; and (ii) for any purpose
                                         other than an Initial Indication, from the first of the (a) or (b) conditions to be achieved
                                         in Section 2.11.2 (i) for the remainder of the Term of this Agreement. Company
                                         may seek a waiver pursuant to Section 2.11.4 should Company wish to engage in
                                         the research, discovery and/or development of a Cue Platform Biologic beyond the purposes
                                         outlined above.

 

		2.11.3	Company Forbearance.

 

		2.11.3.1	From the Effective
                                         Date until the earlier of a) Achievement of Proof of Mechanism for the first Cue Biologic,
                                         or b) eighteen (18) months after Company’s written notice to the Joint Steering
                                         Committee of the First Collaborative Cue Biologic, Company hereby covenants and agrees
                                         that it will not alone or with Third Parties research, develop, make, have made, use,
                                         sell, offer for sale, import, or otherwise exploit, or license any rights in intellectual
                                         property to, any Peptide or biologic in the treatment of an Autoimmune Disease. Company
                                         shall, and shall cause its Affiliates to, furthermore expressly exclude from the scope
                                         of any license, assignment, transfer, conveyance, grant, agreement or covenant between
                                         Company (and/or an Affiliate) and a Third Party any rights with respect to any Peptide
                                         or biologic for the treatment of an Autoimmune Disease. During this period, Company may
                                         seek a waiver pursuant to Section 2.11.4 should Company wish to engage in the research,
                                         discovery and/or development of a Cue Platform Biologic for the treatment of an Autoimmune
                                         Disease.

 

		2.11.3.2	From Proof of
                                         Mechanism for the first Cue Biologic to the end of the Agreement Term.
                                         Company hereby covenants and agrees that it will not alone or with Third Parties research,
                                         develop, make, have made, use, sell, offer for sale, import or otherwise exploit, or
                                         license any rights in intellectual property to, use of any Peptide or biologic in the
                                         treatment of an Initial Indication. Company shall, and shall cause its Affiliates
                                         to, furthermore expressly exclude from the scope of any license, assignment, transfer,
                                         conveyance, grant, agreement or covenant between Company (and/or an Affiliate) and a
                                         Third Party any rights with respect to any Peptide or biologic for the treatment of an
                                         Initial Indication.

 

		2.11.4	[****].
From the Effective Date until [***], and subject to the provisions of Section 2.11.6 below relating to Company Candidates,
Company may [***].

 

    	 	18	 

     

    

 

		2.11.5	Discontinued
                                         Initial Indication.

 

		2.11.5.1	Merck Discontinuance.
                                         Subject to the provisions of Section 2.11.6 below relating to Company Candidates,
                                         following the Research Program Term, should Merck decide through an authorized executive
                                         committee to discontinue the Research, Development and/or Commercialization of any Compound
                                         or Product for one of the Initial Indications, Merck shall promptly provide written notice
                                         (“Merck Discontinuance”) to Company of same (such Initial Indication
                                         a “Discontinued Initial Indication”), and Company shall have the opportunity
                                         upon Company notification to the Joint Steering Committee to engage in the Research and
                                         Development of a Peptide or biologic for such Discontinued Initial Indication; [***].
                                         Such Company notification shall, subject to the provisions of Section 2.11.6,
                                         constitute a waiver with respect to Company’s obligations pursuant to any of Sections
                                         2.11.1 through 2.11.3 with respect to such Discontinued Indication. Company
                                         may request a review by a Merck authorized executive committee as referred to in this
                                         Section 2.11.5 to determine whether the Research, Development and Commercialization
                                         of any Compound or Product for an Initial Indication should be discontinued if a period
                                         of eighteen (18) months has passed since Merck has provided a Progress Report pursuant
                                         to Section 3.5 showing active Research, Development or Commercialization of a
                                         Compound or Product and Merck has not made a decision to discontinue Research, Development
                                         and Commercialization of any Compound or Product for such Initial Indication through
                                         an authorized executive committee.

 

		2.11.5.2	Company Discontinuance.
                                         Notwithstanding the foregoing, if the Research Program Term expires and Merck is
                                         not continuing to Research, Develop or Commercialize a Product Candidate having as a
                                         component thereof an Indication Specific Peptide in any allele which is associated with
                                         one of the Initial Indications, such one Initial Indication shall constitute a Discontinued
                                         Initial Indication and Company shall have the opportunity upon Company notification to
                                         the Joint Steering Committee (“Company Discontinuance”) to engage
                                         in the Research and Development of a Peptide or biologic for such Discontinued Initial
                                         Indication, [***]

 

    	 	19	 

     

    

 

		2.11.6	Company
                                         Candidate(s).

 

		2.11.6.1	Company Candidate(s).
                                         Following the earlier of: (i) the first waiver granted pursuant to Section 2.11.4
					 ; or (ii) the discontinuance of any Research, Development
                                         and Commercialization of any Compound or Product for an Initial Indication pursuant to
                                         Section 2.11.5, until the date which is [***] after the end of the Research Program
                                         Term, Company shall provide to Merck by January 1st and June 1st
                                         of each Calendar Year a written summary of Company’s activities in researching,
                                         developing or commercializing a Cue Platform Biologic pursuant to a waiver granted in
                                         Section 2.11.4, or a Peptide or biologic for
                                         a Discontinued Indication pursuant to Section 2.11.5. No written summary is required
                                         in the event that Company has no such activities. In the event that: (i) Company: (a)
                                         researches or develops a Cue Platform Biologic during the Research Program Term pursuant
                                         to a waiver granted in Section 2.11.4 and said
                                         Cue Platform Biologic is researched or developed for an Initial Indication; or (b) researches
                                         or develops a Peptide or biologic for a Discontinued Initial Indication pursuant to Section
                                         2.11.5 during the Research Program Term or within the [***] period after the end
                                         of the Research Program Term; and (ii) such Cue Platform Biologic, Peptide or biologic,
                                         as applicable, demonstrates a biologically significant effect in testing consistent with
                                         that required to achieve Proof of Mechanism in Table 3 of Schedule 2.1 Research
                                         Program (“Company Candidate”), then Company shall so notify Merck and provide
                                         Merck with the information in Company’s possession relating to such Company Candidate
                                         and the testing to establish Proof of Mechanism. Thereafter, Merck shall have ninety
                                         (90) days (the “Evaluation Period”) in which to inform Company in writing
                                         whether it wishes to designate such Company Candidate as a Proposed Product Candidate.
                                         During the Evaluation Period, Company shall promptly provide Merck with any additional
                                         information relating to the Company Candidate in Company’s possession that is requested
                                         by Merck, and the Parties shall extend the Evaluation Period as reasonably necessary
                                         in order to: (i) perform any additional testing required to establish Proof of Mechanism
                                         as set forth in this Agreement; and (ii) provide Merck with a reasonable period of time
                                         to consider such additional testing. The obligations of this provision shall apply regardless
                                         of whether the Agreement has been previously terminated. Company (and its Affiliates)
                                         shall not assign, transfer, convey or otherwise grant to any Person or otherwise encumber
                                         (including through lien, charge, security interest, mortgage, encumbrance or otherwise)
                                         any rights to a Company Candidate or any Company Know-How, Company Patent Rights or
                                         Company’s interest in Joint Patent Rights related to said Company Candidate (or
                                         any rights to any intellectual property that would otherwise be included in such Company
                                         Know-How, Company Patent Rights or Joint Patent Rights), in any manner that is inconsistent
                                         with or would interfere with the grant of the rights or licenses to Merck in this Section
                                         2.11.6; and any such assignment, transfer, conveyance
                                         or grant of rights or licenses from Company or an Affiliate in violation thereof or inconsistent
                                         therewith shall be void ab initio.

 

		2.11.6.2	Designation of
                                         a Company Candidate as a Proposed Product Candidate. In the event that Merck agrees
                                         in writing during the Evaluation Period to designate the Company Candidate as a Proposed
                                         Product Candidate, then Merck shall commence Commercially Reasonable Efforts to Research,
                                         Develop and Commercialize the Proposed Product Candidate under the same financial terms
                                         contained in this Agreement, including payment of the [***] milestone for Proof of Mechanism
                                         set forth in Section 5.2.1 if such milestone
                                         has not previously been paid; and the definition of “Cue Biologic”, for all
                                         purposes in the Agreement including definitions directly and indirectly reliant thereon
                                         (e.g., Product Candidate, Compound, Product), shall thereafter be amended to include
                                         the Company Candidate. In the event that this Agreement has been terminated prior to
                                         such designation, then the Parties shall execute a new agreement for such Company Candidate
                                         which shall contain: (i) the same financial terms; (ii) an exclusive license from Company
                                         to Merck for Merck to make, have made, use, import, offer to sell and sell said Company
                                         Candidate (and Compound or Product derived therefrom); and (iii) substantially similar
                                         other terms to this Agreement as relevant to a Proposed Product Candidate, Product Candidate,
                                         Compound and Product (as if derived from a Company Candidate), including but not limited
                                         to the treatment of confidential information and intellectual property resulting from
                                         said Company Candidate (and Proposed Product Candidate, Product Candidate, Compound or
                                         Product derived therefrom) or the research, development, manufacture and commercialization
                                         thereof; together with such other terms as the Parties deem appropriate at that time.

 

		2.11.6.3	Non-Designation
                                         of a Company Candidate as a Proposed Product Candidate. In the event that Merck does
                                         not agree in writing during the Evaluation Period to designate such Company Candidate
                                         as a Proposed Product Candidate, then Company shall have no other obligation to Merck
                                         regarding such Company Candidate and Company’s further research and development
                                         of the Company Candidate shall not violate the exclusive efforts provisions of Section
                                         2.11.

 

    	 	20	 

     

    

 

		2.12	Compliance with Law and Ethical Business Practices.

 

		2.12.1	Company shall conduct the activities of the Research Program in accordance with all relevant applicable
laws, rules and regulations including, without limitation, all current governmental regulatory requirements concerning Good Laboratory
Practices. Company shall notify Merck in writing of any deviations from applicable regulatory or legal requirements if Company
becomes aware of any such deviation. Company hereby certifies that it has not and will not employ or otherwise use in any capacity
the services of any person or entity debarred under Section 21 USC 335a in performing any services hereunder. Company shall notify
Merck in writing immediately if any such debarment occurs or comes to its attention, and shall promptly remove any person or entity
so disbarred from performing any activity or function or capacity related to the Research Program. Merck shall have the right,
in its sole discretion, to terminate this Agreement immediately in the event that Company fails to promptly remove any such persons.

 

		2.12.2	Company acknowledges that Merck’s corporate policy requires that Merck’s business must
be conducted within the letter and spirit of the law. By signing this Agreement, Company agrees to conduct the services contemplated
herein in an ethical, reasonable and lawful manner.

 

		2.12.3	Specifically,
Company warrants that none of its employees, agents, officers or other members of its management are officials, officers, agents,
representatives of any government or international public organization. –NOTE: FOR A LIST OF "American
institutions of research, public international organizations and designations under the International Immunities Act"
SEE Section 316.20 at http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&SID=d2739abeb6ca1764c5defa8607248f64&n=8y1.0.1.3.68&r=PART&ty=HTML#8:1.0.1.3.68.0.1.14
Company shall not make any payment, either directly or indirectly, of money or other assets, including but not limited to the
compensation Company derives from this Agreement (hereinafter collectively referred as a “Payment”), to government
or political party officials, officials of international public organizations, candidates for public office, or representatives
of other businesses or persons acting on behalf of any of the foregoing (hereinafter collectively referred as “Officials”)
where such Payment would constitute violation of any law. In addition regardless of legality, Company shall make no Payment either
directly or indirectly to Officials if such Payment is for the purpose of influencing decisions or actions with respect to the
subject matter of this Agreement or any other aspect of Merck’s business.

 

    	 	21	 

     

    

 

		2.12.4	Company acknowledges that no employee of Merck or its Affiliates shall have authority to give any
direction, either written or oral, relating to the making of any commitment by Company or its agents to any Third Party in violation
of terms of this or any other provisions of this Agreement.

 

		2.12.5	Company certifies to Merck that as of the date of this Agreement that Company has screened itself,
and its officers, directors and employees against the Exclusions Lists and that it has informed Merck whether Company, or any of
its officers or directors has been in Violation. After the execution of this Agreement, Company shall notify Merck in writing immediately
if any such Violation occurs or comes to its attention.

 

		2.12.6	Company’s failure to abide by the provisions of Section 2.12 shall be deemed a material
breach of this Agreement. In the event that Company fails to cure such failure within the time specified in Section 8.3.1(a)
after being notified by Merck of such failure, Merck may in such case and with immediate effect terminate this Agreement at its
sole discretion upon written notice to Company and without prejudice to any other remedies that may be available to Merck.

 

		2.12.7	Company shall indemnify and hold Merck and any of its Affiliates harmless from and against any
and all liabilities (including all costs and reasonable attorneys’ fees associated with defending against such claims) that
may arise by reason of the negligent or willful acts or omissions of Company or its agents which would constitute a violation of
Section 2.12.

 

		2.12.8	Company shall indemnify and hold Merck and any of its Affiliates harmless from and against any
and all liabilities (including all costs and reasonable attorneys’ fees associated with defending against such claims) that
may arise by reason of the careless, negligent or willful acts or omissions of Third Parties acting on Company’s behalf which
would constitute a violation of Section 2.12. [***]

 

		2.13	Use of Human Materials.
If any human cell lines, tissue, human clinical isolates or similar human-derived materials (“Human
Materials”) have been or are to be collected and/or used in the Research Program, Company represents and warrants:
(i) that it has complied, or shall comply, with all applicable laws, guidelines and regulations relating to the collection and/or
use of the Human Materials; and (ii) that it has obtained, or shall obtain, all necessary approvals and appropriate informed consents,
in writing, for the collection and/or use of such Human Materials. Company shall provide documentation of such approvals and consents
upon Merck’s request. Company further represents and warrants that such Human Materials may be used as contemplated in this
Agreement without any obligations to the individuals or entities (“Providers”)
who contributed the Human Materials, including, without limitation, any obligations of compensation to such Providers or any other
Third Party for the intellectual property associated with, or commercial use of, the Human Materials for any purpose.

 

    	 	22	 

     

    

 

		2.14	Animal Research. If animals are used in research hereunder, Company will comply with the
Animal Welfare Act or any other applicable local, state, national and international laws and regulations relating to the care and
use of laboratory animals. Merck encourages Company to use the highest standards, such as those set forth in the Guide for the
Care and Use of Laboratory Animals (NRC, 1996), for the humane handling, care and treatment of such research animals. Company hereby
certifies that it has and shall maintain current and valid accreditation from AAALAC during the Term. Any animals which are used
in the course of the Research Program, or products derived from those animals, such as eggs or milk, will not be used for food
purposes, nor will these animals be used for commercial breeding purposes.

 

Article
3  LICENSE; EXCHANGE OF INFORMATION; DEVELOPMENT AND COMMERCIALIZATION.

 

		3.1	License Grants.

 

		3.1.1	Company hereby grants to Merck an exclusive sublicense (even as to Company) in the Field and in
the Territory under Company’s rights in the Einstein Patent Rights and Einstein Know-How, with the right to grant and authorize
sublicenses, for any and all uses, including without limitation: (i) to make, have made or use Cue Biologics; (ii) to make, have
made, use, import, offer to sell and sell Compound(s) and/or Product(s); and (iii) to otherwise carry out activities contemplated
under this Agreement; all within the Field.

 

		3.1.2	Company hereby grants to Merck an exclusive license (even as to Company) in the Field and in the
Territory under Cue Patent Rights, Cue Know-How, and Company’s interest in Joint Patent Rights, with the right to grant and
authorize sublicenses, for any and all uses, including without limitation: (i) to make, have made or use Cue Biologics; (ii) to
make, have made, use, import, offer to sell and sell Compound(s) and/or Product(s); and (iii) to otherwise carry out activities
contemplated under this Agreement; all within the Field.

 

		3.1.3	[***]

 

		3.1.4	Notwithstanding the
scope of the exclusive sublicenses and licenses granted to Merck under Section 3.1.1 and Section 3.1.2, Company
shall retain the rights under the Company Know-How, Company Patent Rights and Joint Patent Rights during the Research Program Term
solely in connection with performing Company’s obligations under the Research Program in accordance with this Agreement to:
(i) research, develop, make, have made, sell, offer to sell, import and use in the Territory, Cue Biologics, Compounds, Products
and any invention claimed in or covered by Company Patent Rights or Joint Patent Rights; and (ii) use Company Know-How.

 

		3.1.5	[***]

 

		3.2	Non-Exclusive License Grant. In the event that either: (i) the making, have made or use
by Merck or its Related Parties of any Cue Biologics during the term of this Agreement; or (ii) the making, having made, use, import,
offer for sale and/or sale by Merck or its Related Parties of Compound or Product in the Territory would infringe a claim of an
issued letters patent that Company (or its Affiliate) Controls and which patents are not covered by the grant in Section 3.1,
Company hereby grants to Merck, to the extent Company is legally able to do so, a non-exclusive, sublicensable, royalty-free license
in the Territory under such issued letters patent for Merck and its Related Parties to conduct such activities with respect to
the Cue Biologics, Compounds and Products for all activities in the Field.

 

    	 	23	 

     

    

 

		3.3	No Implied Licenses. Except as specifically set forth in this Agreement, neither Party shall
acquire any license or other intellectual property interest, by implication or otherwise, in any Information disclosed to it under
this Agreement or under any patents or patent applications owned or Controlled by the other Party or its Affiliates.

 

		3.4	No Grant of Inconsistent Rights by Company. Company (and its
Affiliates) shall not assign, transfer, convey or otherwise grant to any Person or otherwise encumber (including through lien,
charge, security interest, mortgage, encumbrance or otherwise): (i) any rights to any Company Know-How, Company Patent Rights or
Company’s interest in Joint Patent Rights (or any rights to any intellectual property that would otherwise be included in
the Company Know-How, Company Patent Rights or Joint Patent Rights), in any manner that is inconsistent with or would interfere
with the grant of the rights or licenses to Merck hereunder; (ii) any rights to any Cue Biologic prior to the expiration of the
Research Program Term (provided that Company shall grant to Merck the rights to the Cue Biologics as set forth herein); or (iii)
any rights to any Compounds or Products (provided that Company shall grant to Merck the rights to the Compounds and Products as
set forth herein). Without limiting the foregoing, during the Term, (x) Company (and its Affiliates) shall not use (and shall not
grant to any Third Party the right to use) any Cue Biologics (prior to the expiration of the Research Program Term) or Compounds
or Products for any purposes (including the Research, Development, Manufacturing or Commercialization thereof), except for Company’s
performance of the activities to be performed by Company under the Research Program in accordance with this Agreement and (y) Company
(and its Affiliates) shall not provide or otherwise transfer to any Third Parties any Company Know-How which constitutes Cue Biologics-Specific
Information and Inventions, for use in the Field.

 

		3.5	Development and Commercialization. Merck shall use Commercially
Reasonable Efforts, at its own expense, to Research, Develop and Commercialize a Compound or Product. Company shall timely supply
adequate and sufficient amounts of Product Candidates through IND Enabling Studies for each Product Candidate. Merck shall reimburse
Company for its reasonable expenses in supplying such adequate and sufficient amounts. Following the Research Program Term, upon
Company’s written request which shall be no more frequently than once per year, Merck shall provide a written summary of
Merck’s activities in Researching, Developing and/or Commercializing a Compound or Product (“Progress Report”).

 

		3.6	Excused Performance. In addition to the provisions of Article
6, the obligations of Merck with respect to any Product under Section 3.5 are expressly conditioned upon the continuing
absence of any adverse condition or event relating to the safety or efficacy of the Compound or Product, and the obligation of
Merck to Research, Develop or Commercialize any such Compound or Product shall be delayed or suspended so long as in Merck’s
good faith determination any such condition or event exists. Where such adverse condition or event exists, Merck will provide written
notice as soon as practicable of a delay or suspension exercised under this Section 3.6.

 

    	 	24	 

     

    

 

		3.7	Regulatory Matters. In the event that Merck determines that any
regulatory filings for any Compounds and/or Products are required for any activities hereunder (including any activities under
the Research Program), including INDs, NDAs and other Marketing Authorizations (as applicable), then as between the Parties, Merck
(or its Affiliate or Related Party) shall have the sole right, in its discretion, to obtain such regulatory filings (in its (or
its Affiliate’s or its Related Party’s) name) and as between the Parties, Merck (or its Affiliate or its Related Party)
shall be the owner of all such regulatory filings. As between the Parties, Merck (or its Affiliate or Related Party) shall have
the sole right to communicate and otherwise interact with Regulatory Authorities with respect to the Compounds and/or Products
(including during the Research Program Term). For clarity, Company shall have no right to, and shall not, make any regulatory filings
related to any Compounds or Products or otherwise interact with any Regulatory Authorities with respect to the Compounds or Products.

 

		3.8	Sublicenses. Merck shall ensure that all sublicenses of the Cue
Patent Rights and Cue Know-How granted by Merck under this Agreement comport with the terms of this Agreement, and that all sublicenses
of the Einstein Patent Rights and Einstein Know-How granted by Merck under this Agreement comport with the terms of this Agreement
and the Amended and Restated Einstein License Agreement. 

 

Article
4  CONFIDENTIALITY AND PUBLICATION.

 

		4.1	Nondisclosure Obligation. All Information disclosed by one Party
to the other Party hereunder shall be maintained in confidence by the receiving Party and shall not be disclosed to any Third Party
or used for any purpose except as set forth herein without the prior written consent of the disclosing Party, except to the extent
that such Information:

 

		4.1.1	is known by the receiving Party at the time of its receipt, and not through a prior disclosure
by the disclosing Party, as documented by the receiving Party’s business records;

 

		4.1.2	is in the public domain by use and/or publication before its receipt from the disclosing Party,
or thereafter enters the public domain through no fault of the receiving Party;

 

		4.1.3	is subsequently disclosed to the receiving Party by a Third Party who may lawfully do so and is
not under an obligation of confidentiality to the disclosing Party;

 

		4.1.4	is developed by the receiving Party independently of Information received from the disclosing Party,
as documented by the receiving Party’s business records;

 

		4.1.5	is disclosed to governmental or other regulatory agencies in order to obtain patents on Inventions
in accordance with Article 7 herein or to gain or maintain approval to conduct clinical trials on Compound or Product or
to market Product, but such disclosure may be only to the extent reasonably necessary to obtain such patents or approvals;

 

		4.1.6	is deemed necessary by Merck to be disclosed to Related Parties, agent(s), consultant(s), and/or
other Third Parties for any and all purposes Merck and its Affiliates deem necessary or advisable in the ordinary course of business
to achieve the objectives of this Agreement on the condition that such Third Parties agree to be bound by confidentiality and non-use
obligations that substantially are no less stringent than those confidentiality and non-use provisions contained in this Agreement;
provided, however, that the term of confidentiality for such Third Parties shall be no less than ten (10) years; or

 

    	 	25	 

     

    

 

		4.1.7	is deemed necessary by counsel to the receiving Party to be disclosed to such Party’s attorneys,
independent accountants or financial advisors for the sole purpose of enabling such attorneys, independent accountants or financial
advisors to provide advice to the receiving Party, on the condition that such attorneys, independent accountants and financial
advisors agree to be bound by the confidentiality and non-use obligations contained in this Agreement; provided, however,
that the term of confidentiality for such attorneys, independent accountants and financial advisors shall be no less than ten (10)
years.

 

		4.1.8	is deemed necessary by the receiving Party to be disclosed to such Party’s executives, management
and other advisors, including but not limited to members of the Board of Directors and/or Scientific Advisory Board, consultants,
bankers, lenders, existing and prospective bona fide investors, and prospective merger and/or acquisition partners (“Representatives”)
on the following conditions: [***].

 

Any combination of features or disclosures
shall not be deemed to fall within the foregoing exclusions merely because individual features are published or available to the
general public or in the rightful possession of the receiving Party unless the combination itself and principle of operation are
published or available to the general public or in the rightful possession of the receiving Party.

 

If a Party is required by judicial
or administrative process (including a request for discovery received in an arbitration or litigation proceeding), or by a statute,
regulation or rule of law (e.g., securities laws, rules and regulations), to disclose information that is subject to the non-disclosure
provisions of this Section 4.1 or Section 4.2, such Party shall promptly inform the other Party of the disclosure
that is being sought in order to provide the other Party an opportunity to challenge or limit the disclosure obligations. Information
that is disclosed by judicial or administrative process shall remain otherwise subject to the confidentiality and non-use provisions
of this Section 4.1 and Section 4.2, and the Party disclosing information pursuant to law or court order shall take
all steps reasonably necessary, including without limitation obtaining an order of confidentiality, to ensure the continued confidential
treatment of such information. The Parties will consult and cooperate fully with each other on the provisions of this Agreement
to be redacted in any filings made by the Parties with the Securities and Exchange Commission or similar governmental agency in
the U.S. or abroad, or as otherwise required by law.

 

		4.2	Company Know-How. During the period from the Effective Date until achievement of Proof of
Mechanism for the first Cue Biologic, Company agrees to keep all Company Know-How specifically related to any Cue Biologic, Compound,
Product, Indication Specific Peptide, or any Peptide or biologic which is of utility for [****] confidential subject to Section 4.1. Upon achievement of Proof of Mechanism for the first Cue Biologic, Company
agrees to keep all Company Know-How specifically related to any Cue Biologic, Compound, Product, Indication Specific Peptide or
any Peptide or biologic which is of utility for [****] confidential subject to Section 4.1. In the event
that a Company Candidate is not designated as a Proposed Product Candidate pursuant to Section 2.11.6.3, then with respect
to such Company Know-How which is specifically related to to such Proposed Product Candidate (and not related to any other molecule
which is a subject of the Agreement) Company’s obligations of confidentiality shall cease.

 

    	 	26	 

     

    

 

		4.3	Publication. Each Party to this Agreement recognizes that the publication or disclosure of papers,
presentations, abstracts or any other written or oral presentations regarding results of and other information regarding the subject
matter of this Agreement, including the Research Program, may be beneficial to both Parties. Each Party also recognizes the mutual
interest in obtaining valid patent protection and in protecting business interests and trade secret information. Accordingly, except
for disclosures permitted pursuant to Section 4.1 each Party shall have the right to review and approve any paper or presentation
proposed for disclosure by the other Party which utilizes data related to the Research Program, Cue Biologic, Compound or Product
and/or includes confidential Information of the other Party. Before any such paper or presentation is disclosed, the Party proposing
disclosure shall deliver a complete copy to the other Party at least sixty (60) days prior to submitting the paper to a publisher
or making the presentation to a Third Party. The reviewing Party shall have the right (a) to propose modifications to the publication
or presentation for patent reasons, trade secret reasons or business reasons or (b) to request a reasonable delay in publication
or presentation in order to protect patentable information. If the reviewing Party requests a delay, the publishing Party shall
delay submission or presentation for a period of up to ninety (90) days as necessary to enable patent applications protecting each
Party's rights in such information to be filed in accordance with Article 7. Upon expiration of such ninety (90) days, the publishing
Party shall be free to proceed with the publication or presentation. Notwithstanding the foregoing, if the reviewing Party requests
modifications to the publication or presentation including the deletion of certain proprietary information, the publishing Party
shall edit such publication to prevent disclosure of trade secret or proprietary business information (including but not limited
to information related to Cue Biologics-Specific Information and Inventions) prior to submission of the publication or presentation.
The disclosing Party shall comply with any such requests of the reviewing Party.

 

		4.4	Publicity/Use of Names/Press Releases.
No disclosure of the existence, or the terms, of this Agreement may be made by either Party, and no Party shall use the name, trademark,
trade name or logo of the other Party, its Affiliates or their respective employee(s) in any publicity, promotion, news release
or disclosure relating to this Agreement or its subject matter, without the prior express written permission of the other Party,
except as may be required by law. If a Party is required by a statute, regulation or rule of law (e.g., securities laws, rules
and regulations), to disclose the existence, or the terms, of this Agreement or the name, trademark, trade name or logo of the
other Party, such Party shall promptly inform the other Party of the disclosure that is being sought and provide for a period of
at least ten (10) days, or if the period provided by statute, regulation or rule of law is less than ten (10) days, the maximum
period allowable thereunder in order to provide the other Party an opportunity to review the disclosure, provide comments, and
challenge or limit the disclosure obligations. Information that is disclosed shall remain otherwise subject to the confidentiality
and non-use provisions of Section 4.1 and Section 4.2, and the Party disclosing information shall take all steps
reasonably necessary, to ensure the continued confidential treatment of such information. The Parties will furthermore consult
and cooperate fully with each other on the provisions of this Agreement to be redacted in any filings made by the Parties with
the Securities and Exchange Commission or similar governmental agency in the U.S. or abroad, or as otherwise required by law.

 

Article
5  PAYMENTS; ROYALTIES AND REPORTS

 

		5.1	License Fee. In consideration
for the licenses and other rights granted to Merck herein under the Company Patent Rights, Company
Know-How and Company’s interest in Joint Patent Rights, upon the terms and conditions contained herein, Merck
shall pay to Company US$ 2,500,000 (two million five hundred thousand) payable within thirty (30) days after the Effective Date.
Company shall use these funds to pay for Contract Research as that term is defined in the Amended and Restated Einstein License
Agreement.

 

    	 	27	 

     

    

 

		5.2	Milestone Payments.
 Subject to the terms and conditions of this Agreement, Merck shall pay to Company the following milestone payments,
for which Merck or any Related Party achieves, or Company achieves and Merck confirms, the following milestone events hereunder
during the Term:

 

		5.2.1	Research Collaboration Milestones.

 

	 	 	Milestone Event	 	Payment to Company
	1.	 	[***]	 	[***]
	2.	 	[***]	 	[***]

 

		5.2.2	Development and Regulatory Milestones.

 

	 	 	Milestone Event	 	Payment to Company
	3.	 	[***]	 	[***]
	4.	 	[***]	 	[***]
	5.	 	[***]	 	[***]
	6.	 	[***]	 	[***]
	7.	 	[***]	 	[***]
	8.	 	[***]	 	[***]
	9.	 	[***]	 	[***]

 

		5.3	Merck
                                         shall notify Company in writing within sixty (60) days following the achievement of each
                                         milestone set forth in Section 5.2.1 and Section 5.2.2. With respect to
                                         the achievement of a milestone under Section 5.2.1 and milestones 1-9 under Section
                                         5.2.2, Merck shall make the appropriate milestone payment within sixty (60) days
                                         after the achievement of such milestone. Unless otherwise agreed, the payments for
                                         Milestone Event 1 and at least the first two successful Proofs of Concept for Milestone
                                         Event 2 shall be used by Company to pay for “Contract Research” as that term
                                         is defined in the Amended and Restated Einstein License Agreement. The milestone
                                         payments pursuant to Section 5.2.1 and Section 5.2.2 shall be payable only
                                         upon the initial achievement of such milestone [****]; but in no event shall such milestone
                                         payment be paid [****]. Such milestones are independent of the royalty payments due under
                                         Section 5.4 and shall not offset or affect the payment of any royalty payments
                                         due under Section 5.4.

 

    	 	28	 

     

    

 

		5.4	Royalties.

 

		5.4.1	Royalties Payable By Merck. Subject to the terms and conditions of this Agreement, Merck
shall pay Company royalties, calculated on a Product-by-Product basis, as set forth in Section 5.4.

 

		(a)	Patent Royalties. Subject to the provisions of Section 5.4.1(b), Merck shall pay
Company royalties in an amount equal to the following percentage of Net Sales of Products by Merck or its Related Parties where
the sale of Product would infringe a Valid Patent Claim in the country of sale:

 

		(1)	[***] of Net Sales in the Territory in each Calendar Year up to and including [***];

 

		(2)	[***] of Net Sales in the Territory in each Calendar Year for the portion of Net
Sales exceeding [***] up to and including [***]; and

 

		(3)	[***] of Net Sales in the Territory in each Calendar Year for the portion of Net
Sales exceeding [***].

 

		(b)	Know-How Royalty. Notwithstanding the provisions of Section 5.4.1(a), in countries
where the sale of Product by Merck or its Related Parties would not infringe a Valid Patent Claim, Merck shall pay royalty rates
that shall be set at [***] of the applicable royalty rate determined according to Section 5.4.1(a). Such royalties shall
be calculated after first calculating royalties under Section 5.4.1(a).

 

		(c)	Royalty tiers pursuant to Section 5.4.1(a) and Section 5.4.1(b) shall be calculated
based on Net Sales of each Product in the Territory, provided that the determination of whether the royalty shall be calculated
under Section 5.4.1(a) or Section 5.4.1(b) shall be determined on a country-by-country basis. Royalties on each Product
at the rates set forth above shall continue on a country-by-country basis until the expiration of the later of: (i) the last-to-expire
Valid Patent Claim claiming the Compound; or (ii) for a period of ten (10) years after First Commercial Sale of such Product in
such country (the “Royalty Period”).

 

		(d)	All royalties are subject to the following conditions:

 

		(i)	that only one royalty shall be due with respect to the same unit of Product;

 

		(ii)	that no royalties shall be due upon the sale or other transfer among Merck or its Related Parties,
but in such cases the royalty shall be due and calculated upon Merck’s or its Related Party’s Net Sales to the first
independent Third Party;

 

		(iii)	no royalties shall accrue on the sale or other disposition of Product by Merck or its Related Parties
for use in a Clinical Trial; and

 

		(iv)	no royalties shall accrue on the disposition of Product in reasonable quantities by Merck or its
Related Parties as samples (promotion or otherwise) or as donations (for example, to non-profit institutions or government agencies
for a non-commercial purpose).

 

    	 	29	 

     

    

 

		5.4.2	Change in Sales Practices. The Parties acknowledge that during the term of this Agreement,
Merck’s sales practices for the marketing and distribution of Product may change to the extent to which the calculation of
the payment for royalties on Net Sales may become impractical or even impossible. In such event the Parties agree to meet and reasonably
discuss in good faith new ways of compensating Company to the extent currently contemplated under Section 5.4.1.

 

		5.4.3	Royalties for [****]. In those cases in which [****], the royalty obligations of this Section 5.4 shall be applicable
to the compensation and/or other amount of consideration received by Merck [****].

 

		5.4.4	Compulsory Licenses. If a compulsory license is granted to a Third Party with respect to
Compound or Product in any country in the Territory with a royalty rate lower than the royalty rate provided by Section 5.4.1,
then the royalty rate to be paid by Merck on Net Sales in that country under Section 5.4.1 shall be reduced to the rate
paid by the compulsory licensee.

 

		5.4.5	[***]

 

		5.4.6	Royalty Rates. Notwithstanding any provision in this Agreement, where a royalty payment
is due in a particular country, in no event shall Merck pay royalty rates on Net Sales of any Product in such country that are
less than [***]. Accordingly, [***] the royalty rate can under no circumstance go lower than [***].

 

		5.5	Reports; Payment of Royalty.
During the term of this Agreement following the First Commercial Sale of a Product, Merck shall furnish to Company a quarterly
written report for the Calendar Quarter showing the Net Sales of all Products subject to royalty payments sold by Merck and its
Related Parties in the Territory during the reporting period and the royalties payable under this Agreement. Subject to the provisions
of Section 9.2.2, if applicable, such reports shall be sufficiently detailed so as to permit company to independently determine
the accuracy of the amount of royalties paid. Reports shall be due on the sixtieth (60th) day following the close of each Calendar
Quarter. Royalties shown to have accrued by each royalty report shall be due and payable on the date such royalty report is due.
Merck shall keep complete and accurate records in sufficient detail to enable the royalties payable hereunder to be determined.

 

		5.6	Audits.

 

		5.6.1	Upon the written request of Company and not more than once in each Calendar Year, Merck shall permit
an independent certified public accounting firm of nationally recognized standing selected by Company and reasonably acceptable
to Merck, at Company’s expense, to have access during normal business hours to such of the records of Merck as may be reasonably
necessary to verify the accuracy of the royalty reports hereunder for any Calendar Year ending not more than twenty-four (24) months
prior to the date of such request. The accounting firm shall disclose to Company only whether the royalty reports are correct or
incorrect and the amount of any discrepancy. No other information shall be provided to Company. The accounting firm shall be given
copies of all documents needed to accurately perform the accounting, with all provisions and terms necessary to accurately perform
the accounting being unredacted.

 

    	 	30	 

     

    

 

		5.6.2	If such accounting firm correctly identifies an underpayment by Merck during such period, then
Merck shall pay to Company the amount of the discrepancy within thirty (30) days of the date Company delivers to Merck such accounting
firm’s written report so correctly concluding, or as otherwise agreed upon by the Parties. The fees charged by such accounting
firm shall be paid by Company, except in the situation that the accounting firm determines that Merck has underpaid by the greater
of [***] or [***] the royalties it owed for any Calendar Year reviewed by the accounting firm. If such accounting firm correctly
identified an overpayment by Merck during such period, then such overpayment shall be withheld from a next payment due from Merck
to Company.

 

		5.6.3	Merck shall include in each sublicense granted by it pursuant to this Agreement a provision requiring
the sublicensee to make reports to Merck, to keep and maintain records of sales made pursuant to such sublicense and to grant access
to such records by Company’s independent accountant to the same extent required of Merck under this Agreement.

 

		5.6.4	Upon the expiration of twenty-four (24) months following the end of any Calendar Year, the calculation
of royalties payable with respect to such Calendar Year shall be binding and conclusive upon Company, and Merck and its Related
Parties shall be released from any liability or accountability with respect to royalties for such Calendar Year.

 

		5.6.5	Company shall treat all financial information subject to review under this Section 5.6 or
under any sublicense agreement in accordance with the confidentiality and non-use provisions of this Agreement, and shall cause
its accounting firm to enter into an acceptable confidentiality agreement with Merck and/or its Related Parties obligating it to
retain all such information in confidence pursuant to such confidentiality agreement.

 

		5.7	Payment Exchange Rate. All payments to be made by Merck to Company
under this Agreement shall be made in United States dollars and may be paid by check made to the order of Company or bank wire
transfer in immediately available funds to such bank account in the United States as may be designated in writing by Company from
time to time. In the case of sales outside the United States, the rate of exchange to be used in computing the monthly amount of
currency equivalent in United States dollars due Company shall be made at the monthly rate of exchange utilized by Merck in its
worldwide accounting system. 

 

		5.8	Income Tax Withholding. Company shall be liable for all income
and other taxes (including interest) (“Taxes”) imposed upon any payments made
by Merck to Company under this Article 5 (“Agreement Payments”). If
applicable laws, rules or regulations require the withholding of Taxes because of Company’s tax obligations, Merck shall
make such withholding payments and shall subtract the amount thereof from the Agreement Payments. For clarity, Merck shall not
deduct from Agreement Payments any Taxes withheld by Merck to satisfy Merck’s tax obligations. Merck shall submit to Company
appropriate proof of payment of the withheld Taxes as well as the official receipts within a reasonable period of time. Merck shall
provide Company reasonable assistance in order to allow Company to obtain the benefit of any present or future treaty against double
taxation which may apply to the Agreement Payments.

 

    	 	31	 

     

    

 

Article
6 REPRESENTATIONS AND WARRANTIES

 

		6.1	Representations and Warranties of Each
Party. Each Party represents and warrants to the other Party that as
of the Effective Date:

 

		6.1.1	such Party is duly organized and validly existing under the laws of the state or jurisdiction of
its organization and has full corporate right, power and authority to enter into this Agreement and to perform its obligations
hereunder;

 

		6.1.2	the execution and delivery of this Agreement and the consummation of the transactions contemplated
hereby have been duly authorized by the necessary corporate actions of such Party. This Agreement has been duly executed by such
Party. This Agreement and any other documents contemplated hereby constitute valid and legally binding obligations of such Party
enforceable against it in accordance with their respective terms, except to the extent that enforcement of the rights and remedies
created thereby is subject to bankruptcy, insolvency, reorganization, moratorium and other similar laws of general application
affecting the rights and remedies of creditors; and

 

		6.1.3	the execution, delivery and performance by such Party of this Agreement and any other agreements
and instruments contemplated hereunder will not: (i) in any respect violate any statute, regulation, judgment, order, decree or
other restriction of any governmental authority to which such Party is subject; (ii) violate any provision of the corporate charter,
by-laws or other organizational documents of such Party; or (iii) constitute a material violation or breach by such Party of any
provision of any material contract, agreement or instrument to which such Party is a party or to which such Party may be subject
although not a party.

 

		6.2	Company Representations and Warranties.
Company represents and warrants to Merck that as of the date of this Agreement:

 

		6.2.1	all Patent Rights within the Company Patent Rights are in full force and effect, and, to the best
of Company’s knowledge, the Company Patent Rights and Company Know-How exist and are not invalid or unenforceable, in whole
or in part;

 

		6.2.2	it has the full right, power and authority to enter into this Agreement, to perform the activities
hereunder, including the Research Program, and to grant the license and sublicense granted hereunder (including under Article
3);

 

		6.2.3	it (and its Affiliates) has not prior to the Effective Date: (i) assigned, transferred, conveyed
or otherwise encumbered its right, title and interest in Company Patent Rights or Company Know-How; or (ii) otherwise granted any
rights to any Third Parties that would conflict with the rights granted to Merck hereunder;

 

		6.2.4	it is the sole and exclusive owner or licensee of the Cue Patent Rights and Cue Know-How, all of
which are (and shall be, in the case of Company Information and Inventions) free and clear of any liens, charges and encumbrances,
and no other person, corporate or other private entity, or governmental entity or subdivision thereof, has or shall have any claim
of ownership whatsoever with respect to the Cue Patent Rights and Cue Know-How;

 

    	 	32	 

     

    

 

		6.2.5	to the best of Company’s knowledge, it is the sole and exclusive licensee of the Einstein
Patent Rights and Einstein Know-How, all of which are free and clear of any liens, charges and encumbrances, and no other person,
corporate or other private entity, or governmental entity or subdivision thereof, has or shall have any claim of ownership whatsoever
with respect to the Einstein Patent Rights and Einstein Know-How, with the exception that Company is aware that the United States
Government has sponsored certain related research of Albert Einstein and may have certain rights in any subject inventions resulting
therefrom;

 

		6.2.6	to the best of Company’s knowledge, the exercise of the license granted to Merck under the
Company Patent Rights and Company Know-How, including without limitation the Research, Development, Manufacture, use, sale and
import of Cue Biologics, Compounds and Products do not interfere with or infringe any intellectual property rights owned or possessed
by any Third Party other than Albert Einstein;

 

		6.2.7	there are no claims, judgments or settlements against or owed by Company (or any of its Affiliates)
and no pending or threatened claims or litigation relating to the Company Patent Rights and Company Know-How;

 

		6.2.8	to the best of Company’s knowledge, Company has disclosed to Merck all reasonably relevant
information which Company reasonably believes to be necessary for Merck to accomplish the goals of the Research Program and any
additional information requested by Merck regarding: (i) the Cue Biologics, Compounds or Products; and/or (ii) the Company Patent
Rights and Company Know-How licensed under this Agreement, including: (a) any licenses and material agreements related to the Company
Patent Rights, Company Know-How, Cue Biologics, Compounds and/or Products; and (b) and safety or efficacy information related to
the Cue Biologics, Compounds and/or Products;

 

		6.2.9	Company has disclosed to Merck the existence of any patent opinions related to the Company Patent
Rights and Company Know-How licensed under this Agreement;

 

		6.2.10	neither it nor any of its Affiliates has received any written notification from a Third Party that
the Research, Development, Manufacture, use, sale or import of Cue Biologics, Compounds or Products infringes or misappropriates
the Patent Rights or know-how owned or controlled by such Third Party, and Company has no knowledge that a Third Party has any
basis for any such claim;

 

		6.2.11	Company has complied with all existing country-specific laws and regulations involving inventor
remuneration associated with the Company Patent Rights, including Article 6 of the Third Amendment of Chinese Patent Law;

 

		6.2.12	Schedule 1.1 sets forth a true, correct and complete list of Company Patent Rights existing
as of the Effective Date and such schedule contains all application numbers and filing dates, registration numbers and dates, jurisdictions
and owners. The Company Patent Rights and Company Know-How constitute all intellectual property owned or otherwise controlled (through
license or otherwise) by Company (or any of its Affiliates) as of the Effective Date that are necessary or useful for (or otherwise
used by Company or any of its Affiliates in connection with), the Cue Biologics, Compounds and/or Products or the Research, Development,
Manufacture, Commercialization and/or use thereof;

 

    	 	33	 

     

    

 

		6.2.13	to the best of Company’s knowledge, Company has disclosed to Merck all material information
and data which Company reasonably believes to be necessary for Merck to accomplish the goals of the Research Program and any additional
information requested by Merck, in each case related to the Research Program and/or any Cue Biologics, Compounds or Products, regardless
of whether such data and information would have a positive, negative or neutral impact on the potential commercial, scientific
or strategic value or attractiveness of the Research Program, any Cue Biologics, Compounds or Products;

 

		6.2.14	Company has obtained all necessary consents, approvals and authorizations of all governmental authorities
and other Persons required to be obtained by it as of the Effective Date, as applicable, in connection with the execution, delivery
and performance of this Agreement;

 

		6.2.15	neither Company nor any of its Affiliates has obtained, or filed for, any INDs, NDAs or Marketing
Authorizations for any Cue Biologics, Compounds or Products, and, to the best of Company’s knowledge, no other Person has
obtained, or filed for, any INDs, NDAs or Marketing Authorizations for any Cue Biologics, Compounds or Products;

 

		6.2.16	to the best of Company’s knowledge, Company (and its Affiliates) has not employed or otherwise
used in any capacity, and will not employ or otherwise use in any capacity, the services of any Person debarred under United States
law, including under Section 21 USC 335a or any foreign equivalent thereof, with respect to the Cue Biologics, Compounds or Products
or otherwise in performing any portion of the Research Program.

 

		6.2.17	to the best of Company’s knowledge, all research and development (including non-clinical
studies) related to the Cue Biologics, Compounds and/or Products prior to the Effective Date has been conducted in accordance with
all Applicable Laws;

 

		6.2.18	except for the Third Party licenses and agreements resulting from the receipt of certain grants
by Albert Einstein from the United States Government, there are no agreements (including any licenses), written or oral, granting
any licenses or other rights to (or from) Company (or any of its Affiliates) relating to the Cue Biologics, Compounds or Products
or the Company Know-How or Company Patent Rights;

 

		6.2.19	with respect to each Third Party license: (i) it is in full force and effect; (ii) neither Company
nor any of its Affiliates is in breach thereof; (iii) neither Company nor any of its Affiliates has received any notice of breach
or notice of threatened breach thereof; and (iv) neither Company nor any of its Affiliates has received any notice from the counterparty
to such Third Party license of intent to reduce the scope of the field thereof or render any of the licenses thereunder non-exclusive,
and no event, act or omission has occurred which could give rise to the right of the counterparty to such Third Party license to
reduce the scope of the field thereof or render any of the licenses thereunder non-exclusive;

 

		6.2.20	to the best of Company’s knowledge, all information and data provided by or on behalf of
Company to Merck on or before the Effective Date in contemplation of this Agreement was and is true and accurate and complete in
all material respects, and Company has not intentionally disclosed, failed to disclose, or cause to be disclosed, any information
or data that would reasonably be expected to cause the information and data that has been disclosed to be misleading in any material
respect; and

 

    	 	34	 

     

    

 

		6.2.21	it has or ensures that it will have the resources and capabilities to do the work contemplated
by the Research Program.

 

For purposes of
the above representations, the phrase “to the best of Company’s knowledge” means that the employee(s) of the
Company with responsibility for the matter have conducted a reasonable inquiry regarding such matter.

 

		6.3	Company Third Party License Agreements Representations, Warranties and Covenants. Company
represents and warrants to Merck that it has provided to Merck as of the Effective date a true, correct and complete copy of each
relevant Company Third Party license agreements, and each such copy includes any and all amendments, restatements, side letters,
and other modifications thereto, as each such Company Third Party license agreement is in effect as of the Effective Date. Company
further covenants and agrees that during the Term, (a) it shall satisfy all of its obligations under (including making all payments),
and take all steps to maintain in full force and effect, each such relevant Company Third Party license agreements; (b) it will
not assign (except an assignment to a party to which this Agreement has been assigned as permitted under Section 9.2), amend,
restate, amend and restate, terminate in whole or in part, or otherwise modify any of the Company Third Party license agreements
necessary or useful to Merck’s exercise of the rights granted in this Agreement without the prior written consent of Merck;
(c) it will provide Merck with prompt notice of any claim of a breach under any of the Company Third Party license agreements or
notice of termination of any of the Company Third Party license agreements, made by either Company or the counterparty to such
Company Third Party license agreement (or any party acting on behalf of such counterparty); and, (d) it will promptly send to Merck
copies of all other material correspondence to or from the counterparty to such Company Third Party license agreement related to
such Company Third Party license agreement. For the purposes of clarity, Company (and not Merck) shall be responsible for all of
the financial and other obligations of Company (and/or any of its Affiliates) under any of the Company Third Party license agreements,
including any and all financial obligations thereunder with respect to Net Sales of Merck and its Related Parties. Merck shall
have the right, in its sole discretion, to terminate this Agreement immediately upon written notice to Company pursuant to Section
8.3, in the event that Company is in breach of this Section 6.3.

 

Article
7  PATENT PROVISIONS.

 

		7.1	[****]

 

		 	 

 

    	 	35	 

     

    

 

 

		(a)	Merck shall have the sole right to file, prosecute, maintain and defend patent applications on
Merck Information and Inventions (“Merck Other Information and Inventions”);

 

		(b)	Company shall have the sole right to file, prosecute, maintain and defend patent applications on
Company Information and Inventions (“Company Other Information and Inventions”); and

 

		(c)	The Patent Committee will review proposed patent filings pertaining to Joint Other Information
and Inventions. A Party that believes that a patent application should be filed regarding any Joint Information and Inventions
which constitute Other Information and Inventions (“Joint Other Information and Inventions”) shall bring the
matter to the attention of the Patent Committee and the Patent Committee shall discuss how to proceed. If Merck takes the lead
in filing and prosecuting the application, then the Parties shall follow the general procedure described in Section 7.1.1.
If Company takes the lead in filing and prosecuting the application, then the Parties shall follow the general procedure described
in Section 7.1.2. If both Parties agree that a patent application regarding any Joint Information and Inventions should
be filed, then the Parties will split the costs evenly or as otherwise agreed. If only one Party believes that a patent application
regarding any Joint Information and Inventions should be filed, then that Party shall bear all costs unless the Parties agree otherwise.

 

		7.1.4	Patent Term Extension. The
Parties shall cooperate fully with each other to provide necessary information and assistance, as the other Party may reasonably
request, in obtaining patent term extension or supplemental protection certificates or their equivalents in any country in the
Territory where applicable to Company Patent Rights and Joint Patent Rights. In the event that elections with respect to obtaining
such patent term extension are to be made, Merck shall have the right to make the election and Company agrees to abide by such
election.

 

		7.1.5	Other Cooperation. The Parties agree to cooperate fully and provide any information and
assistance that either may reasonably request for the filing, prosecution and maintenance of Company Patent Rights and Joint Patent
Rights, including but not limited to the preparation and filing of any terminal disclaimers and other documents required to procure
and preserve the protections under Applicable Law for all Company Patent Rights and Joint Patent Rights relevant to a Compound
or Product. The Parties further agree to take reasonable actions to maximize the protections available under the safe harbor provisions
of 35 U.S.C. 102(c) for U.S. patents and patent applications.

 

		7.1.6	Filing, Prosecution and Maintenance Expenses. Unless stated otherwise herein, with respect
to all filing, prosecution and maintenance activities under this Section 7.1, the filing and/or prosecuting Party shall
be responsible for payment of all costs and expenses related to such activities.

 

		7.1.7	Inventor Remuneration. Company shall comply with all applicable country-specific inventor
remuneration laws and regulations, including Article 6 of the Third Amendment of Chinese Patent Law associated with Company
Patent Rights and Joint Patent Rights when inventor remuneration obligations are triggered by an employee of Company and/or its
Affiliates, or a Third Party acting on behalf of Company and/or its Affiliates.

 

    	 	36	 

     

    

 

		7.2	Interference, Derivation, Opposition, Reexamination, Reissue, Supplemental Examination, Inter
Partes Review and Post-Grant Review Proceedings.

 

		[****]	 

 

		 	 

 

    	 	37	 

     

    

 

		7.2.3	Cooperation. In connection with any administrative proceeding under Section 7.2.1
or Section 7.2.2, Merck and Company shall cooperate fully and provide each other with any information or assistance that
either may reasonably request. The Parties shall keep each other informed of developments in any such action or proceeding, including
the status of any settlement negotiations and the terms of any offer related thereto. For any proceeding not controlled by Merck,
Company shall obtain prior approval from Merck of any settlement offer or settlement agreement. For any proceeding specifically
related to Platform Information and Inventions which is not controlled by Company, Merck shall obtain prior approval from Company
of any settlement offer or settlement agreement.

 

		7.2.4	Expenses. The Party controlling any administrative proceeding pursuant to Section 7.2.1
and Section 7.2.2 shall bear all expenses related thereto, unless the Parties agree otherwise.

 

		7.3	Enforcement and Defense.

 

		7.3.1	[****]

 

		7.3.2	The Party having the first right to initiate and prosecute legal action pursuant to Section
7.3.1 shall promptly inform the other Party if it elects not to exercise its first right under Section 7.3.1 to initiate
and prosecute legal action, and the other Party shall thereafter have the right to either initiate and prosecute such action or
to control the defense of such declaratory judgment action in its name and, if necessary, the name of the other Party. The costs
of any agreed-upon course of action to terminate infringement of Company Patent Rights or Joint Patent Rights or misappropriation
or misuse of Company Know-How, including without limitation the costs of any legal action commenced or the defense of any declaratory
judgment, shall be paid by the Party initiating and/or prosecuting the action. Each Party shall have the right to be represented
by counsel of its own choice.

 

    	 	38	 

     

    

 

		7.3.3	For any action to terminate any infringement of Company Patent Rights or Joint Patent Rights or
any misappropriation or misuse of Company Know-How pursuant to Section 7.3.1, in the event that a Party is unable to initiate
or prosecute such action solely in its own name, the other Party will join such action voluntarily and will execute and cause its
Affiliates to execute all documents necessary for the Party to initiate litigation to prosecute and maintain such action under
this Section 7.3. In connection with any action or potential action, Merck and Company will cooperate fully and will provide
each other with any information or assistance that either may reasonably request, including cooperating with regard to any pre-litigation
review of the Company Patent Rights and Joint Patent Rights. Each Party shall keep the other informed of developments in any action
or proceeding. For any proceeding not controlled by Merck, Company shall obtain prior approval from Merck of any settlement offer
or settlement agreement. For any proceeding specifically related to Platform Information and Inventions not controlled by Company,
Merck shall obtain prior approval from Company of any settlement offer or settlement agreement.

 

		7.3.4	Any recovery obtained by either or both Merck and Company in connection with or as a result of
any action contemplated by this Section 7.3, whether by settlement or otherwise, shall be shared in order as follows:

 

		(a)	the Party which initiated and prosecuted the action shall recoup all of its costs and expenses
incurred in connection with the action;

 

		(b)	the other Party shall then, to the extent possible, recover its costs and expenses incurred in
connection with the action; and

 

		(c)	the amount of any recovery remaining shall then be allocated between the Parties on a pro rata
basis taking into consideration the relative economic losses suffered by each Party.

 

		7.3.5	Company shall inform Merck of any matter of which it becomes aware concerning the submission of
an application to the U.S. Food & Drug Administration under Section 351(k) of the U.S. Public Health Services Act (42 USC 262(k)),
or to a similar agency under any similar provisions in a country in the Territory, seeking approval of a biosimilar or interchangeable
biological product with regard to which Merck is a reference product sponsor involving Company Patent Rights or Joint Patent Rights
(“Biosimilar Application”). Company shall provide Merck with the unopened Biosimilar Application within three (3) days
of receipt. Notwithstanding the foregoing provisions of Article 7, Merck shall have the sole right, in its discretion, to
control any legal action and any activity taken to resolve a dispute with respect to any infringement of Company Patent Rights
or Joint Patent Rights with respect to any Biosimilar Application, including selection of any patents for listing under 42 U.S.C.
§262(l), and Company shall have no rights in connection therewith. For any action with respect to any infringement of Company
Patent Rights or Joint Patent Rights with respect to any Biosimilar Application, in the event that Merck is unable to initiate
or prosecute such action solely in its own name, Company will join such action voluntarily and will execute and cause its Affiliates
to execute all documents necessary for Merck to initiate, prosecute and maintain such action. In connection with any action, Company
shall cooperate with Merck and provide Merck with information and assistance that Merck may reasonably request, including as defined
in Section 7.3.3.

 

    	 	39	 

     

    

 

Article
8  TERM AND TERMINATION

 

		8.1	Term and Expiration. This
Agreement shall be effective as of the Effective Date and unless terminated earlier pursuant to Section 8.2 or Section
8.3, this Agreement shall continue in full force and effect until one or more Products has received Marketing Authorization
and, thereafter, until expiration of all royalty obligations hereunder. In the event that [***].

 

		8.2	Termination by Merck. Notwithstanding
anything contained herein to the contrary, Merck shall have the right to terminate this Agreement at any time in its sole discretion
by giving thirty (30) days’ advance written notice to Company. For the avoidance of doubt, termination by Merck under this
Section 8.2 can be effected only through a written notice specifically referring to this Section 8.2. No later than
thirty (30) days after the effective date of such termination, each Party shall return or cause to be returned to the other Party
all Information in tangible form received from the other Party and all copies thereof; provided, however, that each
Party may retain one copy of Information received from the other Party in its confidential files for record purposes. In the event
of termination under this Section 8.2: (i) each Party shall pay all amounts then due and owing as of the termination date;
and (ii) except for the surviving provisions set forth in Section 8.4, the rights and obligations of the Parties hereunder
shall terminate as of the date of such termination; provided, however, that upon payment of the License Fee pursuant
to Section 5.1 Merck shall have a fully paid-up non-exclusive license under Company Information and Inventions and Company’s
interest in Joint Information and Inventions to [***]. Upon termination, the Parties shall confer to determine how the Joint Patent
Rights will be addressed.

 

		8.3	Termination for Cause.

 

		8.3.1	Cause for Termination. This Agreement may be terminated at any time during the term
of this Agreement:

 

		(a)	upon written notice by either Party if the other Party is in breach of its material obligations
hereunder by causes and reasons within its control and has not cured such breach within ninety (90) days after notice requesting
cure of the breach; provided, however, in the event of a good faith dispute with respect to the existence of a material
breach, the ninety (90) day cure period shall be tolled until such time as the dispute is resolved pursuant to Section 9.7;
or

 

		(b)	by either Party upon the filing or institution of bankruptcy, reorganization, liquidation or receivership
proceedings, or upon an assignment of a substantial portion of the assets for the benefit of creditors by the other Party; provided,
however, that in the case of any involuntary bankruptcy proceeding such right to terminate shall only become effective if
the Party consents to the involuntary bankruptcy or such proceeding is not dismissed within ninety (90) days after the filing thereof.

 

		8.3.2	Effect of Termination for Cause on License.

 

		(a)	If
                                         either Merck or Company terminates this Agreement under Section 8.3.1(a) or Section
                                         8.3.1(b), then Merck’s sublicense(s) and license(s) pursuant to Section
                                         3.1 and Section 3.2 shall terminate as of such termination date and each
                                         Party shall, within thirty (30) days after the effective date of such termination, return
                                         or cause to be returned to the other Party all Information of the other Party in tangible
                                         form and substances or compositions delivered or provided by the other Party, as well
                                         as any other material provided by the other Party in any medium; provided, however,
                                         that each Party may retain one copy of Information received from the other Party in its
                                         confidential files for record purposes.

 

    	 	40	 

     

    

 

		(b)	If
                                         Merck terminates this Agreement under Section 8.3.1(a) for willful conduct of Company resulting in a material
                                         breach of [***], which material breach cannot be
                                         cured within one hundred twenty (120) days of written notice from Merck detailing such
                                         alleged breach, and which uncured material breach results in a material adverse effect
                                         on Merck’s rights under this Agreement, then Merck shall have the option in its
                                         sole discretion to either: (i) pursue all remedies available to it at law or in equity;
                                         or (ii) have as its sole remedy the reduction of any payments pursuant to Article 5 [***], such option to be provided in writing by Merck
                                         to Company within one hundred fifty (150) days of the written notice from Merck detailing
                                         the alleged breach. Notwithstanding the foregoing, if there is a good faith dispute between
                                         the Parties regarding whether there has been such an uncured material breach, such question
                                         shall be determined in accordance with Section 9.7.

 

		(c)	Upon termination of this Agreement by Merck pursuant to Section 8.2, or by Company pursuant
to Section 8.3.1(a), Merck and its Affiliates, sublicensees and distributors shall be entitled, during the twelve (12) month
period immediately following the effective date of termination, to finish any work-in-progress and to sell any Product or Compound
remaining in inventory, in accordance with the terms of this Agreement.

 

		(d)	If this Agreement is terminated by Merck pursuant to Section 8.3.1(b) due to the rejection
of this Agreement by or on behalf of Company under Section 365 of the United States Bankruptcy Code (the “Code”),
all licenses and rights to licenses granted under or pursuant to this Agreement by Company to Merck are, and shall otherwise be
deemed to be, for purposes of Section 365(n) of the Code, licenses of rights to “intellectual property” as defined
under Section 101(35A) of the Code. The Parties agree that Merck, as a licensee of such rights under this Agreement, shall retain
and may fully exercise all of its rights and elections under the Code, and that upon commencement of a bankruptcy proceeding by
or against Company under the Code, Merck shall be entitled to a complete duplicate of or complete access to (as Merck deems appropriate),
any such intellectual property and all embodiments of such intellectual property. Such intellectual property and all embodiments
thereof shall be promptly delivered to Merck: (i) upon any such commencement of a bankruptcy proceeding upon written request therefore
by Merck, unless Company elects to continue to perform all of its obligations under this Agreement; or (ii) if not delivered under
(i) above, upon the rejection of this Agreement by or on behalf of Company upon written request therefore by Merck.

 

The foregoing provisions of Section
8.3.2(d) are without prejudice to any rights Merck may have arising under the Code or other applicable law.

 

		8.4	Termination
                                         of the Amended and Restated Einstein License Agreement. Merck may terminate this
                                         Agreement under Section 8.3.1(a). in the event that the Amended and Restated Einstein License Agreement
                                         between Albert Einstein and Cue is terminated prior to expiration of the last-to-expire
                                         patent rights licensed to Company thereunder. In such event, Merck shall at its option
                                         enter directly into a license with Albert Einstein, or step into a license with Albert
                                         Einstein pursuant to Section 10.07 of the Amended and Restated Einstein License
                                         Agreement dated July 31, 2017, as amended in the Merck Amendment to the Amended and Restated
                                         License Agreement dated November 10, 2017, and the Consent and Waiver Agreement dated
                                         November 14, 2017 between Merck and Albert Einstein. For clarity, if Merck terminates
                                         this Agreement under Section 8.3.1(a) except for
                                         termination due to Company’s willful conduct as set forth in Section 8.3.1(b), then Merck’s sublicense(s) and license(s) pursuant
                                         to Section 3.1, and Section 3.2 shall terminate pursuant to Section 8.3.2(a) and Merck shall have no rights under Company Patent Rights and Company
                                         Know-How unless provided directly from Albert Einstein.

 

		8.5	Effect of Expiration or Termination; Survival. Expiration or
termination of this Agreement shall not relieve the Parties of any obligation accruing prior to such expiration or termination.
Any expiration or termination of this Agreement shall be without prejudice to the rights of either Party against the other accrued
or accruing under this Agreement prior to expiration or termination, including without limitation the obligation to pay royalties
for Product(s) or Compound sold prior to such expiration or termination. The provisions of Article 4 shall survive the expiration
or termination of this Agreement and shall continue in effect for ten (10) years. In addition, the provisions of Article 1,
Article 3, Article 6, Article 7, Article 8, Article 9 and Sections 2.6, 2.8, 2.9, 2.11 and
5.2 - 5.8 shall survive any expiration or termination of this Agreement.

 

    	 	41	 

     

    

 

Article
9  MISCELLANEOUS

 

		9.1	Force Majeure. Neither Party shall be held liable to the other
Party nor be deemed to have defaulted under or breached this Agreement for failure or delay in performing any obligation under
this Agreement to the extent such failure or delay is caused by or results from causes beyond the reasonable control of the affected
Party, potentially including, but not limited to, embargoes, war, acts of war (whether war be declared or not), acts of terrorism,
insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, fire, floods, or other acts of God, or acts,
omissions or delays in acting by any governmental authority or the other Party. The affected Party shall notify the other Party
of such force majeure circumstances as soon as reasonably practical, and shall promptly undertake all reasonable efforts necessary
to cure such force majeure circumstances.

 

		9.2	Assignment/Change of Control. Except as provided in this Section
9.2, this Agreement may not be assigned or otherwise transferred, nor may any right or obligation hereunder be assigned or
transferred, by either Party without the consent of the other Party.

 

		9.2.1	Merck may, without consent of Company, assign this Agreement and its rights and obligations hereunder
in whole or in part to an Affiliate of Merck or in connection with a Change of Control.

 

		9.2.2	Company may assign this Agreement in its entirety to the successor party in connection with a Change
of Control. In the event that there is a Company Change of Control that is a Competing Pharma Change of Control, then Company shall
provide written notice to Merck at least thirty (30) days prior to the completion of such Change of Control, i.e., the closing
of the transaction that results in Change of Control, and Merck shall have the right, at Merck election at any time after such
Change of Control to implement some or all of the following revisions to this Agreement:

 

		(a)	Merck may limit its obligations to provide Company royalty related reports pursuant to Section
5.5 to reporting only Merck’s total royalty obligations; provided that, Merck will, if requested by Company, provide
royalty reports specified in such Section 5.5 to an independent certified public accounting firm for auditing in accordance
with Section 5.6.

 

		(b)	Merck shall have the right to require Company, including the Change of Control party, to adopt
reasonable procedures to be agreed upon in writing with Merck to prevent the disclosure of all Information of Merck and other information
with respect to the Research, Development, Manufacture and Commercialization of Compounds and Products (collectively “Sensitive
Information”) beyond Company personnel having access to and knowledge of Sensitive Information prior to the Change of
Control and to control the dissemination of Sensitive Information disclosed after the Change of Control. The purposes of such procedures
shall be to strictly limit such disclosures to only those personnel having a need to know Sensitive Information in order for Company
to perform its obligations under this Agreement and to prohibit the use of Sensitive Information for competitive reasons against
Merck and its Related Parties, and for Compounds or Products, including without limitation, the use of Sensitive Information for
the research, development or commercialization of competing products.

 

    	 	42	 

     

    

 

		9.2.3	In the event that there is a Company Change of Control: [***].

 

		9.2.4	Any attempted assignment not in accordance with this Section 9.2 shall be void. Any permitted
assignee shall assume all assigned obligations of its assignor under this Agreement.

 

		9.3	Use of Affiliates. Merck shall have the right to exercise its
rights and perform its obligations under this Agreement either itself or through any of its Affiliates.

 

		9.4	Severability. If any one or more of the provisions contained
in this Agreement is held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining
provisions contained herein shall not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s)
adversely affects the substantive rights of the Parties. The Parties shall in such an instance use reasonable efforts to replace
the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical,
implement the purposes of this Agreement.

 

    	 	43	 

     

    

 

		9.5	Notices. All notices which are required or permitted hereunder
shall be in writing and sufficient if delivered personally, sent by facsimile (and promptly confirmed by personal delivery, registered
or certified mail or overnight courier), sent by nationally-recognized overnight courier or sent by registered or certified mail,
postage prepaid, return receipt requested, addressed as follows:

 

	 	if to Company, to:	
        Cue Biopharma, Inc.

        675 West Street

        Cambridge, MA 02142

        Attention: Daniel Passeri, President and CEO

        Email: dpasseri@cuebio.com

	 	 	 
	 	and:	Mark R. Busch

    K&L Gates LLP

    214 North Tryon Street, 47th Floor

    Charlotte, NC 28202

    Phone: 704.331.7440

    Fax: 704.353.3694

    mark.busch@klgates.com
	 	 	 
	 	if to Merck, to:	
        Merck Sharp & Dohme Corp.

        One Merck Drive

        Whitehouse Station, NJ 08889-0100

        Attention: Office of Secretary

        Facsimile No.: (908) 735-1246

	 	 	 
	 	And	
        Merck Sharp & Dohme Corp.

        2000 Galloping Hill Road

        PO Box 539

        Mailstop K-1-4161

        Kenilworth, NJ 07033-1310

        Attention: Senior Vice President,
Business Development

 

or to such other address(es) as the
Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith. Any such notice shall
be deemed to have been given: (a) when delivered if personally delivered or sent by facsimile on a business day (or if delivered
or sent on a non-business day, then on the next business day); (b) on the business day after dispatch if sent by nationally-recognized
overnight courier; or (c) on the fifth (5th) business day following the date of mailing, if sent by mail. The Parties hereby agree
that, to the extent permitted by law, any notice provided in accordance with this Section 9.5 shall constitute due service
of process with respect to any legal proceeding between the Parties arising hereunder and that compliance with the Hague Convention
for the Service of Process, if otherwise applicable, shall not be required.

 

		9.6	Applicable Law. This Agreement shall be governed by and construed
in accordance with the laws of the State of New York without reference to any rules of conflict of laws or renvoi.

 

    	 	44	 

     

    

 

		9.7	Dispute Resolution.

 

		9.7.1	The Parties shall negotiate in good faith and use reasonable efforts to settle any dispute, controversy
or claim arising from or related to this Agreement or the breach thereof (a “Dispute”). Any Party shall give
the other Party written notice of any Dispute not resolved in the normal course of business. Within twenty (20) days from the date
of delivery of such notice, the receiving Party shall submit to the other Party a written response. The notice and response shall
include (a) a statement of that Party's position and a summary of arguments supporting that position, and (b) the name and title
of the executive who will represent that Party and of any other person who will accompany the executive. Within forty-five (45)
days from the date of delivery of the initial notice, the executives of both Parties shall meet at a mutually acceptable time and
place, and thereafter as often as they reasonably deem necessary, to attempt to resolve the Dispute. These executives shall have
the authority to settle the Dispute and shall be at a higher level of management than the persons with direct responsibility for
administration of this Agreement. All negotiations pursuant to this paragraph are confidential and shall be treated as compromise
and settlement negotiations for purposes of applicable rules of evidence.

 

		9.7.2	If the Parties do not fully settle following the procedure in Section 9.7.1, and a Party
wishes to pursue the matter, each dispute, controversy or claim arising from or related to this Agreement or the breach thereof
that is not an “Excluded Claim” shall be brought in the federal court for the Southern District of New York,
if federal jurisdiction is available, or, alternatively, in the state court in the borough of Manhattan, New York City, New York.
Each of the Parties hereby submits to the exclusive jurisdiction of such courts for the purpose of any such litigation; provided,
that a final judgment in any such litigation shall be conclusive and may be enforced in other jurisdictions by suit on the judgment
or in any other manner provided by law. Each party irrevocably and unconditionally agrees not to assert (a) any objection which
it may ever have to the laying of venue of any such litigation in such courts, (b) any claim that any such litigation brought in
any such court has been brought in an inconvenient forum, and (c) any claim that such court does not have jurisdiction with respect
to such litigation. Each party irrevocably
and unconditionally waives any right to a trial by jury and agrees that any of them may file a copy of this paragraph with any
court as written evidence of the knowing, voluntary and bargained-for agreement among the Parties irrevocably to waive its right
to trial by jury in any LITIGATION.

 

		9.7.3	As used in this Section 9.7, the term “Excluded
Claim” shall mean a dispute, controversy or claim that concerns (a) a decision by the Joint Steering Committee,
the Patent Committee, or Merck within the proper scope of the Committee’s authority pursuant to Section 2.4 or Section 2.5,
or an issue concerning the integrity of data submitted to a regulatory agency, neither of which shall be arbitrable or justiciable
in any forum; (b) the validity or infringement of a patent, trademark or copyright; or (c) any antitrust, anti-monopoly or competition
law or regulation, whether or not statutory. Any action concerning Excluded Claims identified in clauses (b) and (c) of this Paragraph
may be brought in any court having jurisdiction.

 

		9.8	Limitation of Liability. Notwithstanding anything to the contrary
contained herein, no party shall be liable to another party under any theory for any special, incidental, indirect, consequential
or other similar damages, or any punitive damages, whether arising directly or indirectly out of the transactions contemplated
by this Agreement. To be clear, neither party shall be entitled to recover for any lost profit or lost sale damages of any kind,
whether those claimed damages are direct or indirect.

 

    	 	45	 

     

    

 

		9.9	Entire Agreement; Amendments. This Agreement, together with the
Schedules and Exhibits hereto, contains the entire understanding of the Parties with respect to the subject matter hereof. Any
other express or implied agreements and understandings, negotiations, writings and commitments, either oral or written, with respect
to the subject matter hereof are superseded by the terms of this Agreement. The Schedules and Exhibits to this Agreement are incorporated
herein by reference and shall be deemed a part of this Agreement. This Agreement may be amended, or any term hereof modified, only
by a written instrument duly executed by authorized representative(s) of both Parties hereto.

 

Notwithstanding anything to the
contrary in the foregoing, that certain confidentiality agreement between the Parties dated as of May 15, 2017, shall remain in
full force and effect with respect to the subject matter thereof and information disclosed thereunder.

 

		9.10	Headings. The captions to the several Articles, Sections and
subsections hereof are not a part of this Agreement, but are merely for convenience to assist in locating and reading the several
Articles and Sections hereof.

 

		9.11	Independent Contractors. It is expressly agreed that Company
and Merck shall be independent contractors and that the relationship between the two Parties shall not constitute a partnership,
joint venture or agency. Neither Company nor Merck shall have the authority to make any statements, representations or commitments
of any kind, or to take any action, which shall be binding on the other Party, without the prior written consent of the other Party.

 

		9.12	Waiver. The waiver by either Party hereto of any right hereunder,
or of any failure of the other Party to perform, or of any breach by the other Party, shall not be deemed a waiver of any other
right hereunder or of any other breach by or failure of such other Party whether of a similar nature or otherwise.

 

		9.13	Waiver of Rule of Construction. Each Party has had the opportunity
to consult with counsel in connection with the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction
that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply.

 

		9.14	Certain Conventions. Any reference in this Agreement to an Article,
Section, subsection, paragraph, clause, Schedule or Exhibit shall be deemed to be a reference to an Article, Section, subsection,
paragraph, clause, Schedule or Exhibit, of or to, as the case may be, this Agreement, unless otherwise indicated. Whenever this
Agreement refers to a number of days, unless otherwise specified, such number refers to calendar days. Unless the context of this
Agreement otherwise requires, (a) words of any gender include each other gender, (b) words such as “herein”, “hereof”,
and “hereunder” refer to this Agreement as a whole and not merely to the particular provision in which such words appear,
(c) words using the singular shall include the plural, and vice versa.

 

		9.15	Business Day Requirements. In the event that any notice or other
action or omission is required to be taken by a Party under this Agreement on a day that is not a business day (excluding notices
required under Section 3.6), then such notice or other action or omission shall be deemed to be required to be taken on
the next occurring business day. 

 

    	 	46	 

     

    

 

Counterparts.
This Agreement may be signed in any number of counterparts (including by facsimile or electronic
transmission), each of which shall be deemed an original, but all of which shall constitute one and the same instrument. After
facsimile or electronic transmission, the Parties agree to execute and exchange documents with original signatures.

 

[Remainder of
page intentionally left blank. Signature page follows.]

 

    	 	47	 

     

    

 

IN WITNESS WHEREOF, the Parties have executed this Agreement
as of the Effective Date.

 

	MERCK SHARP & DOHME CORP.	 	CUE BIOPHARMA, INC.
	 	 	 
	BY:	/s/ [***]	 	BY:	/s/ Daniel Passeri
	 	[***]	 	 	Daniel Passeri
	 	 	 	 	 
	TITLE: Senior Vice President and Global	 	TITLE: President and CEO
	Head of Business Development & Licensing	 	 

 

 

 

 

 

    	 	 	 

     

    

 

 

Schedule 1.1

 

[****]

 

 

    	 	 	 

     

    

 

Schedule 2.1

 

[****]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}]]